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Chapter I
Abstract
Objective: To examine the relations between patient reported outcomes (PROs) within a
conceptual model for adults with sickle cell disease (SCD) ages 18 – 45 years enrolled in the
Sickle Cell Disease Implementation Consortium (SCDIC) registry. We hypothesized that patient
and SCD related factors and barriers to care would independently contribute to functioning as
measured using the PRO domains. Additionally, pain and other SCD related complications are
expected to impact the relation between the variables. Methods: Participants completed a 48item survey that included socio-demographics and PRO measures, such as social functioning,
pain impact emotional distress, and cognitive functioning. Participants reported on lifetime SCD
complications, pain episode frequency, timing and severity, and barriers to medical care.
Healthcare utilization was obtained from medical records abstractions. Results: Higher pain
frequency and severity and history of treatment for depression were associated with higher odds
of worse outcomes in almost all PRO domains, controlling for age and gender for the 2,054
participants. Such social determinants of health as lower household income and unemployment,
particularly due to disability status, were associated with higher odds of worse outcomes.
Reports of fewer individual barriers to care were associated with better outcomes in emotion,
social, cognitive and fatigue domains, while reports of fewer self-reported SCD
complications/treatments were associated with better outcomes in emotion and sleep impact
domains. Conclusions: Study results highlight the importance of the biopsychosocial model to
enhance understanding of the needs of this complex population, and to design multi-dimensional
approaches for providing more effective interventions to improve outcomes.

Keywords: patient reported outcomes, sickle cell disease, implementation science,
conceptual model
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CHAPTER II
Introduction
Sickle cell disease (SCD) is one of the most prevalent genetic blood disorders in the
world (Piel et al., 2013), affecting 100,000 individuals in the United States (Yawn et al., 2014).
Hemolytic dysfunction caused by SCD results in hemoglobin (the protein responsible for
delivering oxygen) to alter the shape, flexibility, and function of red blood cells to become
"sickled," resulting in multi-organ dysfunctions (American Society of Hematology, 2016). The
hallmark of SCD is pain caused by interrelated chronic and acute co-occurring health conditions.
The pervasive nature of SCD morbidities cuts across multiple domains of functioning.
Individuals with SCD must deal with biological (e.g. increase rates of stroke, asthma, and
infection), psychological (e.g. increased rates of depression), and social (e.g. increase challenges
with employment) issues (Aneke & Okocha, 2017; Haywood 2013; Yawn et al., 2014). As such,
it is imperative that research examines the impact of SCD on health-related quality of life
(HRQoL), a multidimensional concept that captures the degree to which an individual's wellbeing and level of functioning, compared to the perceived ideal, is affected by their health
(Dampier, 2011; Panepinto & Bonner, 2012; Shih & Simon, 2008).
Historically, SCD was a life-threatening condition for infants and children (Alrayyes et
al., 2018); however, due to medical advances in the last fifty yeas such as standardized newborn
screening and implementation of penicillin prophylaxis, individuals with SCD live well into
adulthood (Lanzkron et al., 2013; Paulukonis et al., 2016; Powars, et al., 2002). Today, the
cohort of adults with SCD face chronic health complications such as persistent chronic pain,
progressive deterioration of microvasculature causing chronic end-stage vital organ damage, and
neurologic issues (Ballas et al., 2010; Ballas, et al., 2012; Vichinsky, 2017). As a result, many
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adults with SCD experience poor HRQoL due to limited physical, social, and emotional
functioning (Dampier et al., 2011; Tarrt et al., 2015).
Unfortunately, the needs of adults with SCD are not being met due to limited access to
comprehensive care centers (Kaur et al., 2020; Lankzron et al., 2018), a shortage of providers
knowledgeable in the care and treatment of SCD (Grosse et al., 2009; Smith, et al., 2006), and
less funding compared to other chronic illnesses (Farooq & Strouse, 2018). A notable
consequence of these systemic issues are the increased rates of healthcare utilization, morbidity,
and mortality for transition age adults (ages 18-24) with SCD (Brousseau et al., 2010;
Lebensburger et al., 2012; Yusuf et al., 2011). As a result, many adults may be forced to overutilize emergency departments and inpatient settings to receive treatment due to lack of
comprehensive care. It is clear that a large proportion of healthcare costs could be reduced if
adults with SCD received consistent outpatient treatment (Blinder et al., 2013). Admissions for
SCD related issues account for an estimated 115,000 encounters and $500 million per year, with
75% of those encounters made by adults (Brousseau et al., 2010; Singh et al., 2014).
When adults do engage with the healthcare system, they face systemic barriers to care
such as poor provider interactions (Glassberg et al., 2013; Haywood, Lanzkron et al., 2015),
stigma and discrimination (Bulgin et al., 2018; Haywood et al., 2014; Nelson & Hackman, 2013)
and lack of resources and social support (Hankins et al., 2012). Additionally, barriers to care are
compounded by mix of individual and system factors such as transportation limitations,
insurance coverage issues, and disruptions to social-role responsibilities (Mayer et al., 2003;
Smith et al., 2017; Wolfson et al., 2012).
Poor social and emotional functioning for adults with SCD is associated with a
constellation of disease-related factors, patient related factors, and systemic barriers to care
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(Aneke & Okocha, 2017; Mann-Jiles & Morris, 2008). Rates of depression range from 18 - 44%
across several studies of mental health for adults with the disease (Tartt et al., 2015). Research
focused on sociodemographic factors (Asnani et al., 2010; Hasan, et al., 2003), SCD-related
neurologic dysfunction (Mackin et al., 2014; Vichinsky et al., 2010) and somatic symptoms
(Sogutlu et al., 2018; Toumi et al., 2018) demonstrate the complex interrelationships that
negatively impact mental health outcomes for individuals with SCD. Furthermore, many adults
with SCD experience poorer lower mental health functioning due to limited social support and
resources (Jenerette & Murdaugh, 2008; Telfair et al., 2003; Treadwell et al., 2014).
Self-reported measures of functioning are needed to gain insight into the unique
challenges adults with SCD experience (Dampier et al., 2011). Patient-reported outcome
measures provide a subjective perspective of one's health status and level of functioning (Aneke
& Okocha, 2017), and are reliable and feasible methods for assessing HRQoL across different
settings (Bulgin et al., 2019; Esham et al., 2019). Giving voice to adults with SCD is critical in
understanding how to best serve this patient population. Moreover, implementation of resources
and interventions are likely to be more effective when considering patient’s subjective
experience of the disease (Basch et al., 2018).
Identification of problem
SCD has deleterious effects across social, emotional, and physical domains of
functioning (Dampier et al., 2011). This inherited blood disorder fundamentally disrupts essential
biologic functioning resulting in multi-organ failure and high rates of mortality (Yawn et al.,
2014). The interrelated nature of SCD complications results in a feedback process that amplifies
physical, psychological, and social problems (Anie, 2005; Ballas, 2007; Jenerette et al., 2014;
Vichinsky et al., 2010). For example, SCD causes intermittent acute and chronic pain (Brandow

PATIENT REPORTED OUTCOMES IN SICKLE CELL DISEASE

9

& DeBaun, 2018) which significantly limits functioning which contributes to increased anxiety,
low mood, and disrupts role functioning (Edwards et al., 2005; Jonassaint et al., 2016; Levenson
et al., 2008).
The burden of sickle cell disease is experienced both at the individual and systemic
levels. The cumulative impact of SCD is compounded by barriers to care that significantly
contribute to poorer HRQoL compared to the general population (Treadwell et al., 2014). Adults
with SCD face health-related complications due to the progression of the disease into adulthood
while dealing with pressure to navigate healthcare systems with limited support. There are less
comprehensive care centers and fewer knowledgeable providers to treat adults with SCD
compared to children. This inequity in access is shown to contribute to lower HRQoL and
increases rates of mortality for adults with SCD (Hamideh & Alvarez, 2014; Paulukonis et al.,
2016).
A patient-centered approach that encompasses a biopsychosocial model is key to
effectively to treating patients with SCD. Research utilizing PROs provide insight into the
subjective experience of one's well-being and level of functioning, compared to the perceived
ideal, as affected by one's health (Panepinto & Bonner, 2012; Shih & Simon, 2008). The
experiences of adults with SCD have been silenced for decades in America (Burnes et al., 2008;
Nelson & Hackman, 2013; Thompson, 2013). The holistic stance to health outcomes research
that centers the experience of adults with SCD will push for increased support for a historically
underfunded chronic health condition (Farooq & Strouse, 2018).
Rationale and alignment with Jesuit mission
There are only a handful of national studies examining a wide range of health-related
factors. This dissertation will shed light on the contextual factors such as social economic status,
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race, and barriers to care that influence health outcomes for individuals with SCD. Many adults
affected by the disease identify as Black or African American, lack economic resources, rely on
government-funded insurance (i.e., Medicaid and Medicare), and face discrimination when
attempting to seek treatment (Jenerette et al., 2014; Hassell, 2010). We must better understand
the nuances of individual, systemic, and disease related factors to best serve this population.
Furthermore, there is a paucity of funding allocated for SCD compared to other diseases (Farooq
& Strouse, 2018). The lack of funding and attention has led to poorer HRQoL as healthcare
systems are unable to effectively meet the needs of adults with SCD. The burden of the disease
significantly disrupts activities of daily living and lowers social and emotional functioning
(Palermo et al., 2008; Treadwell et al., 2014). Previous research on HRQoL for adults has been
done (Dampier, 2011), but an updated exploration on the impact of SCD is needed.
The findings of this dissertation will inform implementation science strategies to promote
the adoption of evidence-based care in SCD. We will analyze data from a large national cohort
gathered by the Sickle Cell Disease Implementation Consortium (SCDIC) which is funded by the
National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
The SCDIC is a multi-site study that was established in 2016 with the aim of improving the
overall health and well-being of adolescents and adults ages 15 to 45 years with SCD. The
SCDIC is composed of eight academic and clinical centers across the U.S. each enrolling at least
300 adolescents and adults with SCD into a registry. The SCDIC's objectives are to: 1) conduct a
community-based needs assessment of the barriers to care for both local and national
populations, 2) participate in the development of a SCD Registry, in collaboration with clinical
centers and the NHLBI, and 3) design implementation research studies to address identified
barriers to care. The SCDIC is committed to using implementation science, the scientific study of
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the methods to promote systematic adoption and utilization of research findings into routine care
(Bauer, et al., 2015). This research will contribute to the SCDIC’s aim to close the "research to
practice gap," ultimately improving care for more people with SCD in a shorter period.
This dissertation will yield key insights on ways to improve the quality of life of the
whole person, or the cura personalis. The focus on the whole person is in alignment with the
mission of University of San Francisco. The dissertation project will follow USF’s Jesuit spirit
by attending to the social, emotional, and physical aspects of health. Individuals who have SCD
face chronic health disparities and systemic injustices (Haywood et al., 2014; Nelson &
Hackman, 2013). The efforts of the SCDIC more broadly, and this dissertation specifically, are
reflections of USF’s mission to critically examine factors cause injustice for adults living with
SCD and seeks to find solutions to address the problem.
Purpose and aims of dissertation
The purpose of this dissertation is to examine the relations between PROs within a
conceptual model for adults with SCD ages 18 – 45 years enrolled in national SCD data registry.
Participants completed a 48-item Patient Enrollment Survey that included validated self-reported
measures (full or partial measures used) of health and functioning. The first aim was to update
the literature regarding HRQoL for adults with SCD. It has been over a decade since the last
large, multi-national cohort study of adults using measures of HRQoL to examine the
relationship between SCD and PROs (Dampier et al., 2011). Our study will update the field and
inform future research and areas for interventions for SCD. The second aim was to understand
the relationships between patient-related, disease-related, and systemic factors that influence
PROs for adults with SCD. The third aim was to examine the influence of health-behaviors on
PROs for adults with SCD.

PATIENT REPORTED OUTCOMES IN SICKLE CELL DISEASE

12

We hypothesize that patient related and disease related factors along with barriers to care
would independently contribute domains of functioning when measured using validated
measures for PROs. Additionally, given the pervasive impact of pain and comorbid nature of the
disease, we hypothesized that pain and other SCD related complications would account for a
significant degree of the relation between the variables when assessing PRO. Lastly, we
hypothesized a significant bidirectional influence between health behaviors such as adherence
and healthcare utilization on PRO domains.
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Project Specific Definitions
Acute Chest Syndrome (ACS): a range of pulmonary issues (chest pain, cough, fever, hypoxia
(low oxygen levels), lung infiltrates) due to occlusion of the pulmonary vasculature resulting in
life-threatening lung damage
Adult hemoglobin (HbA): the main oxygen transport protein for adults
Avascular necrosis: the deterioration or death of bone tissue due to the lack of blood supply
Cerebral vascular accident (CVA): also known as stroke; death of brain cells due to lack of
oxygen
Chronic transfusion: a blood transfusion provides a person with donated blood via intravenous
injection; chronic transfusions refer to this process occurring regularly (~1x per month) over a
period of time
Fetal hemoglobin (HbF): the main oxygen transport protein in the fetus and persists in the
newborn until roughly 2-6 months of age
Health related quality of life (HRQoL): multi-dimensional concept that includes domains related
to physical, mental, emotional, and social functioning
Hematologic disease: disorders which primarily affect the blood & blood-forming organs
Hemoglobin: oxygen-binding protein, found in erythrocytes, which transports oxygen from the
lungs to the tissues
Hemorrhagic stroke: occurs when weakened blood vessels rupture
Ischemic stroke: occurs when a blood vessel supplying blood to the brain is obstructed
Implementation science: is the study of methods to promote the adoption and integration of
evidence-based practices, interventions and policies into routine health care and public health
settings
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Neuropathic pain: pain caused by damage or disease affecting the somatosensory nervous system
Nociceptive pain: The "felt" experience of pain, relating to the perception or sensation of pain
Microvasculature: Microvessels are the system of small blood vessels in the body, responsible
for circulation
Patient reported outcomes (PRO): the patient's subjective interpretation and report of their own
health status and level of functioning.
Sepsis: potentially life-threatening condition caused by the body's response to an infection,
resulting in multi-organ damage
Sickle cell anemia (SCA): Hemoglobin SS or S0 thalassemia disease, inherited form of anemia,
caused by a lack of healthy red blood cells to carry adequate oxygen throughout the body
Sickle cell trait (SCT): A condition in which a person inherits the sickle cell gene mutation from
one parent and one normal gene from the other
Silent cerebral infarct (SCI): or "silent stroke," is a brain injury without accompanying outward
symptoms of a stroke
Somatization: psychological distress manifested by one or more bodily symptoms
Somatic pain: also known as a form of nociceptive pain. The nerves transmitting somatic pain
are in the skin, or muscles and connective tissues
Somatic symptom burden (SSB): the stress caused by a heightened focus on physical symptoms
such as pain or fatigue which leads to significant emotional and functional problems
Vasculopathy: any disease affecting blood vessels
Vaso-occlusive events (VOEs): also known as acute pain events, caused by obstruction of blood
circulation due to sickled red blood cells resulting in ischemic injury and subsequent pain and
other clinical complication
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CHAPTER III
Review of the Literature
Overview of sickle cell disease
Sickle cell disease (SCD) is one of the most prevalent inherited blood disorders in
the world, impacting an estimated 7 million people globally (Piel et al., 2013; Yawn et al., 2014).
SCD affects 330,000 births annually and accounts for 3.4% of deaths in children ages 1 to 5
years across the world (Modell & Darlison, 2008). Individuals who inherit a combination of
hemoglobin S, C, E, D Punjab, β thalassemia, or α zero (α0) thalassemia may develop a serious
hemoglobin disorder, also known as SCD (Modell & Darlison, 2008). Demographic projections
of SCD calculated an estimated one-third increase in newborns with sickle cell anemia (SCA Hemoglobin SS or S0 thalassemia disease) by the year 2050 (Piel et al., 2013). In the United
States, there are 100,000 individuals currently living with the disease, and about 3.5 million
people are carriers of the sickle cell trait (SCT) (Yawn et al., 2014). Individuals with SCD in the
United States predominantly fall into four genotypes: HbSS (60%), HbSC (30%), and HbSβ0 and
HbSβ+ thalassemia (10%) (Hassell, 2010). SCD type HbSS and HbSβ0 thalassemia are often
associated with increased disease severity, complications, and higher rates of healthcare
utilization (Saraf et al., 2014; Yawn et al., 2014). One out of 365 African American children, and
one out of 16,300 Hispanic-American children are born with SCD in the U.S. every year
(Centers for Disease Control and Prevention [CDC] 2020). SCD is also common in other global
ethnic groups from South America, the Middle East, or South Asia (Brousseau et al., 2010).
SCD is caused by a single point mutation in beta-globin on chromosome 11, producing
an abnormal form of hemoglobin, the protein in red blood cells responsible for delivering oxygen
throughout the body (Musumadi et al., 2012). The hemoglobin gene mutation in SCD produces
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aberrations to the amino acid sequence that limits the production of globin-chains. As a result,
hemoglobin S polymerizes upon deoxygenation, causing red blood cells to become "sickled,"
and die prematurely (Saraf et al., 2014). The sticky, rigid, and "sickled" hemoglobin generate
SCD pathologies that disrupt fundamental hematologic functioning resulting in SCD
complications including vaso-occlusive events (VOEs), ischemia-reperfusion (repeated
obstructions to blood vessels causing tissue damage), hemolytic anemia resulting in chronic
anemia, and sepsis (Chakravorty & Williams, 2015; Rees et al., 2010). Over time, SCD
complications lead to organ dysfunction and intermittent acute and chronic pain (Yawn et al.,
2014).
Multi-organ impact of SCD
SCD is a multi-organ disease with a range of clinical complications throughout the body,
which cause co-occurring acute and chronic health conditions (Alrayyes et al., 2018; Brandow &
DeBaun, 2018; Yawn et al., 2014). The disease interrupts organ functioning leading to liver
dysfunction, pulmonary disease, cerebral atrophy, renal failure, and genitourinary complications
such as priapism (Alrayyes et al., 2018). Additionally, SCD pathology impairs neurologic
functioning and is associated with central nervous system complications such as silent strokes,
overt strokes, seizures, cranial nerve neuropathies, and vascular malformations (Elmariah et al.,
2014; Lanzkron et al., 2013; Paulukonis et al., 2016; Vichinsky et al., 2010). The risk of
hemorrhagic stroke in patients with SCD is 30 times greater compared with those without the
disease (Vichinsky, 2017), and a history of stroke in SCD is correlated with increased risk of
comorbidity and increased rate of mortality (DeBaun et al., 2012; Miller et al., 2001; Strouse, et
al., 2009; Vichinsky et al., 2010).
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There are age-related morbidity patterns in individuals with SCD such as splenic
dysfunction and dactylitis during the first five years, cerebral infarctions in children and
adolescents, and progressive deterioration of microvasculature causing chronic end-stage organ
damage of the kidneys, lungs, brain, bones, and retina during the third and fourth decades of life
(Powars et al., 2002). Consequently, people with SCD need treatment for a range of medical
conditions throughout their lives. The multiorgan dysfunction for adults with SCD cause higher
rates of healthcare utilization compared to people with other chronic diseases such as asthma,
pneumonia, congestive heart failure, and diabetes mellitus (Alrayyes et al., 2018; Brousseau,
2010; Elmariah et al., 2014). There are evidence-based disease-modifying therapies for SCD
including regular blood transfusions and hydroxyurea therapy which are shown to alleviate many
acute and chronic SCD complications (Danielson, 2002; Yawn et al., 2014). Hydroxyurea was
FDA approved over 20 years ago and elevates levels of fetal hemoglobin to help reduce the
number of acute pain events (Yawn et al., 2014). Unfortunately, side effects to hydroxyurea
treatment, lack of knowledge regarding evidence based treatments, and barriers to care can result
in poor treatment adherence (Agrawal et al., 2014). Novel techniques to cure SCD such as
allogeneic bone marrow transplantation and gene therapy are available, but are accessible to a
limited number of patients at this time (Ballas et al., 2010; Yawn et al., 2014).
SCD complications significantly lower quality of life across multiple domains of
functioning for adults with SCD (Andong et al., 2017; Dampier et al., 2011; Luzinete Felix de
Freeitas et al., 2018). SCD complications such as chronic pain have been shown to lower
physical and social functioning (Adegbola, 2015) and are associated with increased prevalence
of mental health disorders (Anie et al., 2012; Beverung et al., 2015; Treadwell et al., 2014).
Patient-related factors such as lower socioeconomic status and issues with insurance coverage
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are also associated poorer health outcomes, high rates of hospital utilization, and increase
mortality (Perimbeti et al., 2018; Powers, 2002). Many adults report that having the disease
significantly disruptions in their social and occupational functioning (Thomas & Taylor, 2002).
In order to maintain proper health, adults with SCD take tremendous efforts associated with
health behaviors such as sleep, pain, hydration, monitor physical exertion, medication
management, and attend medical appointments (Bulgin et al., 2019; Yawn et al., 2014). The
social impact and impact on functioning result in literal costs for adults with SCD. Predictive
modeling indicate that adults with SCD have a substantial reduction in quality-adjusted life
expectancy and lifetime earnings compared with those without the disease (Lubeck et al., 2019).
Despite research highlighting the increased disease burden for adults, particularly as they age
(Adegbola et al., 2012; Dampier et al., 2011; Powers et al., 2002), limited attention has been
given to holistic assessments of functioning of adults with SCD (Keller et al., 2014).
Patient-reported outcomes in SCD
Assessing HRQoL using PROs measures are necessary to understand the complexity of
disease burden on the lives of people with SCD (Aneke & Okocha, 2017). PROs measures
capture the subjective experience of health status, without interpretation from a clinician or
researcher (Deshpande et al., 2011). Recent studies show that validated measures of PROs are
feasible tools to provide an in-depth understanding of patient experiences in clinical settings
(Bulgin et al., 2019; Esham et al., 2019). Additionally, PROs provide valuable insight on how
treatment impacts functioning which can lead to insights to reduce unnecessary admissions and
reduce the overall cost of care (Sarri et al., 2018).
There are few large studies that gather data from multiple sites to understand PROs in
adults with SCD. The last large multisite study, Comprehensive Sickle Cell Centers (CSCC)
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Collaborative Data Project, was completed in 2008. This study found diminished functioning for
adults with SCD across a majority of domains of functioning on the Short Form Health Survey
(SF-36) (Dampier et al., 2011).The CSCC study included 1046 participants with a median age of
28, 48% were male, and 73% were SCD genotype SS or Sβ0 thalassemia. The study found that
female gender was associated with diminished functioning and vitality scores. Disease related
factors such as acute pain events, asthma, and avascular necrosis were each associated with
poorer SF-36 scale scores. Additionally, opioid use was associated with lower functioning and
chronic antidepressant use associated with poorer reports of bodily pain, vitality, social
functioning, emotional role, and mental health scale scores (Dampier et al., 2011).
Pain and health-related quality of life
Pain is a hallmark clinical manifestation of SCD (Musumadi et al., 2012; Piel et al.,
2013; Rees et al., 2010) presenting throughout life (Ballas, 2007; Ballas et al., 2010; Kanter &
Kruse-Jarres, 2013), and is a central driver of lower HRQoL (Ballas, 2007; Moscou-Jackson et
al., 2016; Taylor et al, 2010). SCD pain emerges from four concurrent pathologies: pain
syndromes, anemia related sequelae, multi-organ failures, and comorbid conditions (Ballas,
2005; Ballas et al., 2012). The subjective experiences of pain also take multiple forms leading
poorer health outcomes. SCD pain produces an array of nociceptive, neuropathic, inflammatory
and central pain processes that contribute to poor mental health functioning, somatic issues, and
high healthcare utilization rates (Brandow et al., 2015; Campbell et al., 2016; Dampier et al.,
2017).
Patient-related characteristics such as such as older age, SCD genotypes (HbSS and
HbSß0 thalassemia), gender identified women, and lower socioeconomic status contribute to
poorer health outcomes when linked with pain (Ballas et al., 2010; Killough, 2010; Palermo, et
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al., 2015; Wallen et al., 2014; Zempsky et al., 2017). Beginning in adolescence, acute pain
episodes are superimposed on a backdrop of emergent chronic pain that persists into adulthood
(Ballas et al., 2012; Kaufman et al., 2018; Rees et al., 2010). Increased frequency and intensity
of pain is also associated with a decrease in quality of life (Brandow et al., 2010; Taylor et al.,
2010; Treadwell et al., 2014), and higher rates of mortality (Ballas & Lusardi, 2005).
SCD pain result in significant interference in daily living (Master et al., 2016) and
diminished psychosocial functioning (Aneke & Okocha, 2017; Kaufman et al., 2018; Schlenz et
al., 2016). A vaso-occlusive event (VOE), also known as an acute pain episodes, are disruptive,
taxing, and chaotic experiences. Acute pain episodes last roughly 4 to 11 days, and many
individuals manage pain at home for several days before ultimately seeking medical attention
(Aneke & Okocha, 2017; Dampier et al., 2002; Jacob et al., 2005). The disruption of daily living
due to VOEs are associated with fear, anxiety, depression, and disconnection from activities of
daily life (Ballas 2007; Ballas, Gupta, & Adams-Graves, 2012). The interference caused by SCD
pain limits functioning across multiple domains of functioning (Esham et al., 2019; Kaufman et
al., 2018).). Lastly, pain interference was associated with increased opioid use, low mood, and
decreased levels of engagement (Anie & Steptoe, 2003), while high rates of opioid use for SCD
pain have a significant relationship with somatic symptom burden, stress, negative coping, and
lower physical and mental HRQoL (Smith et al., 2012).
Patient-reported outcome and measures assessing health related quality of life help
stakeholders understand the multifaceted nature of chronic SCD pain (Taylor et al., 2010).
Studies show chronic SCD pain decreases overall functioning and HRQoL (Rees et al., 2010;
Treadwell et al., 2014; Yawn et al., 2014). Chronic SCD pain is linked to increased morbidity
and mortality in both adults and children (Dampier et al., 2017) and is correlated with diminished
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attention, low mood, and challenges with learning and memory (Brandow & DeBaun, 2018;
Pope et al., 2016). The etiology of chronic pain in SCD varies, yet common disease-related
factors include damage to bones and soft tissue, hepatic or splenic enlargement, accumulation of
fluid and other internal damage (Apkarian et al., 2009; Ballas, 2005; Dampier et al.,
2017). Persistent pain undoubtedly impairs functioning. For adults with SCD, daily pain
intensity was associated with lower PROs in the domains of social functioning, pain recall,
energy and fatigue (Ballas et al., 2006). The Pain in Sickle Cell Epidemiology Study (PiSCES)
found that lower scores on PROs were associated with increased bodily pain, lower social
function, and poorer general health compared to adults with asthma (McClish et al., 2005).
Additional studies of subjective reports of functioning consistently show the negative impact of
chronic pain on overall functioning for adults with SCD (Adegbola, 2011, Gil et al., 2004; Smith
et al., 2008).
SCD pain lowers emotional and social functioning in adults with SCD (McClish et al.,
2005; Taylor et al, 2010), and scores on PROs remain lower when compared to other chronic
conditions (McClish et al., 2005). SCD pain alters perception, attention, mood, motivation,
learning and memory (Brandow & DeBaun, 2018; Pope et al., 2016). Increased prevalence of
anxiety and depression are linked to experiencing years of SCD pain, and are subjectively
experienced as low mood, fatigue, and increased stress (Edwards et al., 2005; Simons et al.,
2014). Results from a daily diary study of adults with SCD found 27.6% of participants were
depressed and those who were depressed had more pain days (71.1%) than those who were not
depressed (49.6%) (Levenson et al., 2008). A two-year cross-sectional study of adults with SCD
found worse PRO scores on physical functioning were correlated with somatic comorbidities,
anxiety, and depression (Azarkeivan et al, 2009). Additional research using PROs found negative
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emotions associated with pain were predictive of psychiatric manifestations including
somatization, anxiety, phobic anxiety, and acute psychological symptoms (Edwards et al., 2014).
Socio-emotional functioning in SCD
The detrimental impact of SCD on mental health outcomes cuts across biopsychosocial
domains. Reported rates of depression and anxiety for adults with SCD are two to three times the
national average (Jonassaint et al., 2016). Rates of depression range from 18 - 44% (Tartt et al.,
2015) and adults with SCD are at increased risk for suicide (Edwards et al., 2009). Not
surprisingly, PRO studies with individual with SCD found poorer mental health scores were
associated with lower overall quality of life (Luzinete Felix de Freitas et al., 2018). SCD
complications that lowered HRQoL in PRO measures had significant relationships with lower
psychological well-being and negative coping (Anie, et al., 2012; Keller et al., 2014). Reasons
for poorer mental health outcomes are multifaceted and often co-occur. Several contributing
factors include neurological disruption (Vichinsky et al 2010), comorbid somatic issues (Toumi,
et al., 2018) and challenges with coping and self-efficacy (Anie, 2005). Patient-reported
outcomes measuring mental health in emergency room settings found adults with SCD endorsed
feeling depressed (29%) and anxious (20%) (Smith et al., 2017) and self-report measures of
functioning showed an inverse relationship between patient self-efficacy and hospital utilization
(Cronin et al., 2018).
Neurocognitive issues caused by disease-related sequalae cause problems with
functioning throughout the lifespan for people with SCD. Over time, disease-related
vasculopathy disrupts blood supply to the brain, reduces gray matter and has been linked to
lower cognitive functioning (Mackin et al., 2014; Armstrong et al., 2010; Kato, 2018; Stotesbury
et al., 2018). An estimated one third of individuals with SCD will have an identifiable
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neurological deficit in their lifetime, and the risk of stroke is three times higher in adults with
SCD (Strouse, et al., 2009). Diminished neuropsychological function causes poorer social,
emotional, and occupational functioning for individuals with SCD (Gold et al., 2008; Hijmans et
al., 2011; Lance et al., 2015). When compared to community samples, adults with SCA had
lower global cognitive function, memory, processing speed and executive function (Vichinsky et
al., 2010). Similar findings of lower cognitive functioning for adults with SCD have been found
in the areas of memory (Mazza et al., 2018) and processing speed (Jorgensen et al., 2017).
Unfortunately, a significant proportion of individuals with SCD are likely to have neurocognitive
deficits that go undetected due to lack of routine screening and regular assessment (Schatz &
McClellan, 2006; Vichinsky et al., 2010).
As this review of the literature attempts to highlight, there are several layers of suffering
that people with SCD face. The felt experience, or somatic symptoms of SCD create a burden of
disease that causes poorer health outcomes, increases healthcare utilization, and lowers
functioning (Ballas et al., 2010; Toumi et al., 2018). Somatic conditions of SCD include a broad
range of complications including pulmonary hypertension, leg ulcers, infections, stroke, ocular
damage, progressive renal dysfunction, osteonecrosis, acute chest syndrome and asthma (Toumi
et al., 2018). Research using PROs found that increased somatic symptom burden was
significantly correlated with anxiety and depression as well as a higher number of days in pain
and increased healthcare utilization (Sogutlu et al., 2011). Common somatic concerns are issues
with sleep and increased fatigue which have been shown to diminish health outcomes, reduce
self-efficacy, and reduce quality of life (Adegbolia et al. 2013; Hajibeigi et al., 2009). Fatigue is
associated with higher levels of depressed mood and lower levels of functioning (Amerginer et
al., 2014), and the variability of scores on PRO measures of insomnia was predictive of acute
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pain severity and depression in adults with SCD (Moscou-Jackson et al., 2016). The relationship
between depression and sleep was also examined in a cohort study of 328 adults with SCD,
which found 71.2% met criteria for a sleep disturbance, and 21% scored in the clinically
depressed range on the Beck Depression Inventory II (Wallen et al, 2014).
Many individuals with SCD must carry the burden of their disease with limited social
support and resources. The lack of necessary support negatively influences social and emotional
functioning for adults with SCD (Crosby et al., 2015). Limited social support, lack of
community resources, and challenges to fulfilling role functions have been identified as key
factors that lower HRQoL for adults with SCD (Jenerette & Murdaugh, 2008; Telfair et al.,
2003; Treadwell, et al., 2014). The complexity of managing SCD disease-related factors such as
unpredictable pain events intertwined with systemic challenges such as establishing consistent
comprehensive care limit social and occupational functioning (Adegbola, et al, 2012; Hsu et al.,
2016). Many adults endorse feeling a lack of agency due to their disease. Increased rates of
depressive symptoms were associated with "other people" locus of control domain in a PRO
study of adults with SCD (Gibson et al., 2013). Research utilizing PROs found that isolation
increased rates of depression for adults with SCD compared to controls (Asnani et al., 2010).
Additional research highlights experiences of isolation and reluctance to disclose disease status
as a significant social burden (Treadwell et al., 2014). Lastly, the lack of support and resources
may diminish an individual's ability to cope effectively. The challenges with coping effectively
with SCD results in a deleterious feedback loop of social and emotional issues. Coping with SCD
pain and managing healthcare with limited resources is associated with feelings of fear, anxiety
and depression for adults with SCD (Hasan et al., 2003; Jacob et al., 2005; Schlenz et al., 2016).
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Healthcare Utilization in SCD
Disease-related variables such as acute pain and patient-related variables such as lack of
transportation intersect with system barriers to care such as discrimination to contribute to high
rates of healthcare utilization for adults with SCD (Mitchell, 2018). Additionally, these factors
influence healthcare behaviors such as adherence, which in turn influence utilization rates. The
cyclical effect of these factors produce disproportionally high number of admissions and
healthcare costs (Brousseau et al, 2010). There is clear evidence that significant number of
admissions are potentially preventable with access to comprehensive treatment for people with
SCD (Blinder et al., 2013; Nimmer et al., 2015).
Multiple studies illustrate the disease related variables such as such as genotype and pain
are strong indicators of utilization rates for adults with SCD. High-risk sickle cell genotypes
(HbSS and HbSß0 thalassemia) are associated with higher reports of pain intensity and rates of
healthcare utilization as compared to relatively low-risk groups (HbSC and HbS ß+ thalassemia)
(Brousseau, 2010; Schlenz et al., 2016). Recurrent hospital admissions and readmissions give us
an insight into the factors that contribute to poorer health outcomes. A 2016 study found that
individuals with higher rates of readmissions had more lifetime complications and comorbidities
including acute chest syndrome, increased rates of psychiatric comorbidity, and avascular
necrosis of hip or shoulder (Carroll 2016). Furthermore, somatic symptom burden of SCD such
as pain and depression are associated with increased utilization (Sogutlu, et al., 2011).
Healthcare encounters for adults often occur in emergency departments due to unmanaged pain
in outpatient settings (Jacob et al., 2005; Rees et al., 2010). Each year, an estimated 200,000 ED
visits and 113,000 hospital admissions are related to SCD pain (Yusuf et al., 2010). Notably,
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opioid therapy, which is used to treat SCD pain, was associated with greater levels of clinical
pain, depression, and increased healthcare utilization (Carroll et al., 2016).
Patient-related variables such as age, distance from treatment center, transportation
issues, insurance status, urbanicity, and disease severity are significant factors in healthcare
utilization for adults with SCD (Smith et al., 2017; Wolfson, 2012). A life-course perspective
(Colen, 2011) is needed to appreciate the influence of early-life experiences, particularly related
to economic deprivation and the social disadvantages that shape health outcomes for adults with
SCD. Transition age young adults (18-24) account for a disproportionally high utilization rates
and increased morbidity and mortality rates compared to any other age group (Paulukonis et al.,
2017). The lack of available specialized providers (e.g., hematologists) plays a significant role in
an over-reliance on EDs for care for young adults with SCD (Hemker, et al., 2011). Transition
age adults with SCD are responsible for the highest rates of utilization for both 30-day and 14day re-hospitalization compared to other age groups (Brousseau, 2010) as well as the highest
healthcare cost (Blinder et al., 2013). Unfortunately, high rates of healthcare utilization are
associated with increased SCD complications and the risk of mortality (AlJuburi et al., 2013).
Barriers to care and adherence to treatment
There are evidence-based treatments to manage complications, reduce frequency of
VOEs, and manage chronic pain in SCD (Yawn, et al., 2014). Furthermore, research indicates
that individuals that are adherent to evidence-based therapies such as blood transfusions or
hydroxyurea report better PROs (Luzinete Felix de Freitas et al., 2018; Brandow & Panepinto,
2010). Quality of life measures of social functioning, pain recall, and general health perception
were better for adults who were adherent to hydroxyurea compared to those who were not
(Ballas, 2006). Despite the efficacy and utility of hydroxyurea to improve health in SCD, it
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remains underutilized for adults (Caroll et al., 2013; Lanzkron et al., 2008). Barriers to adherence
to hydroxyurea include side effects such as cytopenia, abnormal spermatogenesis, hair loss, and
nausea. Provider-level barriers include bias towards patients' capacity to remain adherent, fear of
side effects, and lack of knowledge of side-effects of the medication (Brandow & Panepinto,
2010). The provider-level barriers result in lost opportunity for improved health as a study that
found that for those who never used hydroxyurea, 50% never received information about the
drug, and 85% thought they would not see improvement if they took hydroxyurea (Elander et al.,
2011). Barriers to adherence go beyond the patient and provider. System level barriers include
poorer treatment of patients from ethnic minority groups and with socioeconomic challenges that
affect adherence and ability to attend clinic and laboratory appointments (Brandow & Panepinto,
2010).
The opportunity to engage individuals with SCD to adhere with evidenced-based
treatment is often halted by systemic barriers to care. Adults with SCD experience systemic
barriers in healthcare settings such as stigma, discrimination, and lower quality of care received
(Bediako & Moffit, 2011; Bulgin et al., 2018; Haywood et al., 2014). Adults who enter
healthcare settings for acute pain episodes are often met with negative attitudes and biases from
providers (Ratanawongsa et al., 2009). Discriminatory practices towards adults with SCD
include longer wait times (Haywod et al., 2013), prejudice regarding race and functioning (Royal
et al., 2011), and receive inadequate treatment for disease related presentations (e.g., inadequate
analgesia for pain management) (Glassberg et al., 2013). Multiple studies demonstrate the
negative impact of stigma related to SCD on psychological well-being, physiological outcomes,
social connectedness, and care-seeking behaviors (Bulgin et al., 2018). The impact of barriers to
care due to discrimination contribute to poorer health and increase suffering. Adults with SCD
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reported avoiding or waiting to receive care even when pain was very high because of
experiences of discrimination and poor provider interactions such as being labeled a "drug
seeker" (Jenerette et al., 2014). These systemic barriers, such as healthcare discrimination, are
associated with increased stress and reduced quality of life (Ezenwa et al., 2015; Mathur et al.,
2016).
CHAPTER IV
Methods
Model Development
The model examined for this dissertation study was developed from the SCDIC's
Conceptual Framework for PROs/HRQoL in SCD, with input from additional experts in the area
of PROs in SCD (see Figure 1). Our study identified five predictor variables including SCDrelated factors (genotype, disease modifying therapies (hydroxyurea and chronic transfusion
therapy). SCD complications (number of self-reported complications, ASCQ-Me Pain Frequency
and Severity), Health Behaviors (adherence to hydroxyurea, acute healthcare utilization),
Barriers to Care (systemic/access barriers and individual barriers), and Patient-Related Factors
(education, income, employment, marital status, lifetime depression, and diabetes). Our seven
outcome variables are PRO measures assessing pain, sleep and social functioning impacts,
emotional distress, fatigue, and cognitive functioning.
Recruitment Procedures and Enrollment
Data collection into the SCDIC national registry occurred between 2017 and 2018. The
cohort of participants in the registry was 2,433 adolescents and adults ages 15 to 45. The data
collected for the SCDIC Registry included (1) medical record abstraction (provider completed),
(2) laboratory reporting form (clinical/research staff completed with laboratory data pulled from
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central medical databases or electronic health records) and (3) Patient Enrollment Survey (patient
self-report), including questions regarding pregnancies and conception, with a different form
used for men and women. After removing participants with incomplete data (e.g. either a
completed medical record abstraction form or Patient Enrollment Survey) and adolescents, the
study sample was 2,054 (see Figure 2). All baseline patient surveys were completed under the
supervision of study personnel who were available to answer questions as needed. All data
collected was entered into the data coordinating center's Research Electronic Data Capture
(REDCap) system for management, cleaning, and analysis.
During the recruitment phase of the SCDIC, participants were primarily a convenience
sample recruited through SCDIC clinical centers, with some outreach into the community.
Eligible participants were identified and recruited into the registry in various ways such as in
person (e.g. in clinic, EDs), by phone, or via electronic media (e.g. chat rooms, text). For
participants recruited remotely, their consent could be obtained electronically with an online
signature collection website. Screening, approaching, consenting and verifying the eligibility of
potential study participants was conducted by designated SCDIC research staff.
A participant was considered enrolled when consent was obtained, and inclusion criteria met.
Inclusion Criteria
• Age 15 years up to and including 45 years
• English speaking
• Confirmed SCD diagnosis. Confirmed is defined as supported by documentation in the medical
record of a positive test for one of the following: HbSS, HbSC, HbSβ-thalassemia (+ or 0),
HbSO, HbSD, HbSG, HbSE, HbSF. If no medical record was available, the enrolling center
could conduct its own laboratory test as confirmation.
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• Willing and cognitively able to give informed consent and complete the Patient Enrollment
Survey
Exclusion Criteria
• Unwilling or unable to give consent/assent or complete the Patient Enrollment Survey
• Sickle cell trait (e.g., HbAS)
• Successful bone marrow transplant
Participants and informed consent
The SCDIC: "Using Implementation Science to Optimize Care of Adolescents and Adults with
Sickle Cell Disease" is multi-center study with principal investigators from each of the eight
participating sites. The principal investigator for UCSF Benioff Children's Hospital Oakland is
Marsha Treadwell, PhD. The local IRB approval was issued through Hematology/Oncology
Research Studies at UCSF Benioff Children's Hospital Oakland: IRB# 2017-093.
Informed consent occurred in-person (e.g., in clinic or hospital, at SCD community events, at
medical conferences) or via phone. Following consent (and assent where appropriate),
participants completed one baseline survey with two versions (depending on sex/gender
identification) accessible on tablet or paper. Remote consent through mail or online third-party
website was allowed only after the study coordinator walked the participants through the content
of the consent form over the phone. Signed informed consent was obtained prior to any data
collection, and hard copies of the completed and signed consent were given to participants or
parents/guardians. A signed HIPAA Research Authorization was also required of all participants.
The data was collected from participants' medical record abstractions and self-reported
responses on the Patient Enrollment Survey. The Patient Enrollment Survey was not deemed to
pose greater than minimal risk to participants. It was recognized that questions on the survey
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might cause uncomfortable feelings about lifestyle, quality of life, personal or family history of
disease, so protocols to manage any distress that arose during completion of the surveys were put
into place. Participants received a gift card following survey completion but there were no direct
benefits to the participants in the SCDIC Registry. Some participants might benefit from
knowing that their contributions to the study is helping advance the state of the science regarding
SCD treatment.
Patient Reported Outcomes measures
The SCDIC Registry gathers information through the use of common data elements
(CDEs) in SCD developed in such sources as the PhenX Toolkit, ASCQ-Me, and PROMIS
(measures described below) to collect standard clinical measures, laboratory values, lifestyle
factors, medical history, treatment, and healthcare utilization. The measures capture PROs
associated with pain, co-morbidities, quality of life, physical functioning, mental health and
barriers to care. The use of CDEs in the SCDIC registry allows for the identification of gaps in
research, large data queries and analysis, as well as informs future directions of research locally
and nationally.
Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me)
The ASCQ-Me is a PRO measurement system that examines and monitors the physical,
mental, and social well-being of adults with SCD. ASCQ-Me development included formative
research to generate a comprehensive conceptual model of the ways in which SCD affects the
lives of adults in order to develop a SCD-specific quality-of-life measurement system (Keller et
al., 2014; Treadwell et al., 2014). The research team conducted an extensive literature review,
interviews and focus groups with key stakeholders and field testing for validation (Treadwell et
al., 2014). The qualitative research team reached saturation after analysis of additional data until
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no further categories could be identified. The final taxonomy was demonstrated to be reliable for
the classification of qualitative data at the domain level (κ = 0.623, P < 0.0001) and at the
category level (κ = 0.606, P < 0.0001) (Treadwell et al., 2014).
The PRO measures used in this study were the ASCQ-Me Pain, Sleep and Social
Functioning Impact. Pain impact was assessed using two items: "How often did you have very
severe pain?" and "How often did you have pain so bad that it was hard to finish what you were
doing?" over the past week. Sleep impact was also assessed using two items: "How often did you
stay up most of the night because you could not fall asleep?" and "How often did you have a lot
of trouble falling asleep?" over the past week. Social functioning impact was assessed with two
items: "How much did you rely on others to take care of you because of your health?" and "How
much did your health make it hard for you do things with your friends?" over the past 30 days.
All ASCQ-Me items were rated on a 5-point Likert scale, from Never to Always. Item responses
were uploaded to HealthMeasures Scoring Service (https://www.healthmeasures.net/score-andinterpret/calculate-scores) and T-scores were provided in reference to the ASCQ-Me field test
population (n = 556). The ASCQ-Me short forms have demonstrated reliability and validity
(Keller et al., 2017). The standardized T-score mean is 50 (SD = 10), with higher scores
indicating more desirable (better) outcomes.
Patient-Reported Outcomes Measurement Information System (PROMIS)
PROMIS is a system of multiple patient-centered measures that evaluates and monitors
physical, mental, and social health for the general population and those with chronic conditions
(Cella et al., 2010). PROMIS is appropriate for use with both adults and children. PROMIS
measurement development included comprehensive literature reviews of existing measures,
focus groups with relevant stakeholders, and thematic analysis followed by item-review process.
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The validity and reliability of the PROMIS measures has been demonstrated across a variety of
chronic conditions, settings, and populations (Askew et al., 2016; Cook et al., 2016). A 2016
study of a cohort of cancer patients found PROMIS Physical Function short forms showed high
internal consistency (Cronbach's α = 0.92 – 0.96), convergent validity (Fatigue, Pain
Interference, FACT Physical Well-Being all r ≥ 0.68) and discriminant validity (unrelated
domains all r ≤ 0.3) across survey short forms, age, and race-ethnicity (Jensen et al., 2015)
The PRO measures used in this study were Emotional Distress (depressive symptoms)
and Tiredness. Four items from the PROMIS Emotional Distress short form were used to assess
depressive symptoms in the last 7 days including: “I felt worthless,” “I felt helpless,” “I felt
depressed,” and “I felt hopeless.” One item ("I felt tired") from the PROMIS Fatigue item bank
was used to assess tiredness in the past 7 days. PROMIS measures are scored on a 5-point Likert
scale. Item responses were uploaded to HealthMeasures Scoring Service, where T-scores were
provided in reference to the PROMIS Wave 1 representative population (adults) (Liu et al.,
2010). The standardized T-score mean is 50 (SD = 10), with higher scores indicating worse
health outcomes.
Quality of Life in Neurological Disorders (Neuro-QoL)
The Neuro-QoL is a set of self-report measure within the HealthMeasures system that
assesses quality of life associated with the physical, mental, and social effects experienced by
adults and children living with neurological conditions (e.g. stroke, multiple sclerosis,
amyotrophic lateral sclerosis, Parkinson's disease, epilepsy and muscular dystrophy). Since
individuals with SCD are at increased risk for stroke and silent cerebral infarcts, the SCDIC
Registry subcommittee deemed Neuro-QoL an appropriate measurement system to assess
HRQoL associated with cognition for the SCDIC Registry participants. The development phase
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of Neuro-QoL consisted of an extensive literature review, an on-line Request for Information for
feedback from neuroscience scholars, scientists, and clinicians, two phases of in-depth expert
interviews, patient and caregiver focus groups, and individual interviews with patients and
proxies (N = 63). The Neuro-QoL Cognitive Function measure was designed to assess perceived
difficulties in cognitive abilities (e.g., memory, attention, and decision making, or in the
application of such abilities to perform everyday tasks (e.g., planning, organizing, calculating,
remembering and learning). The measure has been normed on an adult population of n = 1,009
and has demonstrated validity and reliability (Gershon et al., 2012; Lai et al., 2018).
The Neuro-QoL Cognitive Function short form was used to assess cognitive functioning.
The measure uses a five item Likert scale (i.e., Never to Very Often / several times a day). Item
responses were uploaded to HealthMeasures Scoring Service where T-scores were provided in
reference to the PROsetta Stone Wave 2 population (adults) (Liu et al., 2010). The standardized
T-score mean is 50 (SD = 10), with higher scores representing better health.
ASCQ-Me Pain Episode Measure – Frequency and Severity
The ASCQ-Me Pain Episode Measure is a five-question measure assessing pain
frequency (number of severe pain events in the last 12 months), timing (of most recent event)
and severity of the most recent sickle cell pain event (including duration and pain interference).
In order to create a “norm-based” interpretation of the scores to represent a comparison to an
average score in some reference population, the scores are placed relative to the average scores
for the 556 adults with SCD who answered ASCQ-Me questions during the field test. Higher
scores indicate worse frequency, timing and severity of SCD pain. ASCQ-Me uses a T-score
metric in which 50 is the mean of the reference population and 10 is the standard deviation (SD)
of that population. That said, a score of 60 would be one standard deviation worse than average
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and a score of 40 would be one-standard deviation better. Internal consistency reliability was
between 0.80 and 0.73 for the fixed form and 0.94 to 0.90 for short forms.
Two separate composite scores are calculated to reflect the frequency and the severity of
the pain episodes. Due to the differences in the number of questions in each composite, these two
scores have different range, which means scores should be standardized through z-score
calculations so they are on the same scale and can be compared.
ASCQ-Me Medical History Checklist (MHC) – SCD Complications
The ASCQ-Me MHC (Keller et al., 2017) is a list of conditions or treatments associated
with SCD. Participants answer "yes" or "no" to a list of 13 (modified from 9) SCD related
conditions (e.g. leg ulcers, hip or shoulder damage, heart failure) or treatments (e.g. medications
taken for pain). The MHC is a cumulative measure of yes/no responses to items such as "have
you ever had open sores on your feet" or "do you take pain medicine every day for your SCD"
along with a list of common complications associated with SCD (e.g. kidney damage, high blood
pressure, asthma). High scores on ASCQ-Me MHC indicate poorer health due to greater number
of health conditions. Participants separately reported on two comorbidities, diabetes and lifetime
treatment for depression, with a follow up question asking if currently in treatment for
depression. Participants also indicated "yes" or "no" to current use of hydroxyurea and blood
transfusions for SCD. Sickle cell genotype (grouped as sickle cell anemia (Hb SS or S 0
thalassemia; Hb SC; Sβ+ and other variants) was obtained from medical record abstraction.
Measurement of Health Behaviors
Health behaviors were assessed using two variables from the medical record abstraction
form: outpatient visit to sickle cell specialist or primary care provider within one year of
enrollment ("yes" or "no") and the number of acute care visits for pain in the past year (combined
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ED or hospital admissions), categorized as 0, 1 - 2 or >= 3 ED/hospital admissions. The other
health behavior was from the Patient Enrollment Survey: currently on hydroxyurea ("yes" or
"no"). If yes, participants reported on their adherence in the past seven days, categorized as: not
adherent" (0 – 1 day); "partially adherent" (2 – 5 days); and "adherent" (6 – 7 days).
Sickle Cell Disease Barriers to Care Checklist
The SCD Barriers to Care consists of 11 reasons for delays in care or not receiving
medical care needed obtained from a longer SCD-specific checklist with demonstrated validity
and reliability (Treadwell et al., 2015). Barriers to care were grouped as individual (4) (e.g. …
too busy with work or other commitments to take the time; previous bad experiences with the
healthcare system) and systemic/access barriers (7) (e.g., … couldn't get an appointment soon
enough, provider’s office too far away, insurance does not cover, co-pays too high) (Treadwell et
al., 2015). The number of individual and systemic/access barriers are summed separately and
together, with higher scores indicating more barriers.
Data analysis
The data collection process occurred from 2017 to 2018. Data was analyzed from the
SCDIC registry database, including data from medical record abstractions and the Patient
Enrollment Surveys. The initial sample size was 2,433 participants ages 15 – 45 years consented
and with confirmed SCD diagnosis. We removed the adolescent group (15 to < 18 years), as well
as those without either a completed medical record abstraction form or Patient Enrollment
Survey for a final sample size for the study of 2,054 adults with SCD (see Figure 2).
Seven patient-reported outcomes (i.e., pain, sleep and social functioning impacts, emotional
distress, tiredness, and cognitive function) were included in the analyses. Binary variables were
created for all outputs using as cutoffs 1 SD above the mean for PROs where a higher T-score
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indicates a worse outcome (PROMIS Emotional Distress and Fatigue scores) and 1 SD below the
mean for those where a higher T-score indicates a better outcome as compared to the reference
populations (all ASCQ-Me scores and Neuro-QoL Cognitive Function score).
Baseline characteristics and distributions of risk factors are presented as frequencies and
percentages for categorical variables, and median and interquartile ranges (IQR) or mean and SD
for continuous variables. Bivariate analysis was used to evaluate potentially signiﬁcant variables
for inclusion in multivariable models. Categorical variables were analyzed using chi-square, or
Fisher’s exact test for sparse tables. Continuous variables were compared using t-test or MannWhitney U test, as appropriate. Two-sided p-values < .05 were considered to be statistically
significant.
Multivariable models were developed for each PRO to identify factors independently
associated with worse outcomes. All variables with p <= .10 in bivariate analysis were included
in a multivariable logistic regression analysis using backward model selection, with an exit
criterion of p < .05. Variables of theoretical importance (i.e., age and gender) as well as
interactions between selected predictors were included in the initial models but none were
significant. Odds ratios and corresponding 95% confidence intervals were obtained for variables
remaining in the final model. All analyses were conducted in SAS Version 9.4 (SAS Institute
Inc., Cary, NC, USA).
CHAPTER V
Results
Socio-demographics
A total of 2,054 adults with SCD were included in the present analysis. As shown in
Table 1, the median age was 28 years, and the predominant age group was 24 – 34 years
(43.8%). Over half (56.8%) identified as female, and the majority identified as African
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American/Black (95.7%), with 4.5% reporting Hispanic ethnicity. The most common educational
attainment was some college (35.2%), followed by high school graduate or equivalent (30.3%),
with 24.1% attaining a college or advanced degree. Over a third (37.2%) were employed, 25.2%
reported being disabled and the remainder were not working, either due to student status
(13.5.%), or “other” (24.1%) including working exclusively in the home or laid off. A significant
proportion (74.2%) were never married and over half (54.6%) reported an annual income under
$25,000. Similar to other SCD populations, almost 60% had Medicaid or other government
sponsored insurance.
Clinical Characteristics, Health Behaviors and Barriers to Care
The majority (72.6%) of participants were diagnosed with sickle cell anemia (SCD
genotypes SS or Beta 0 thalassemia) (see Table 2). Of thirteen potential SCD
treatments/complications, participants reported a median of 3 treatments/complications on the
ASCQ-Me MHC. More than half of the participants (55.9%) reported four or more
treatments/complications, 20.6% reported 2 or 3 and 22.6% reported less than two SCD related
treatments/complications. Less than three percent reported a diagnosis of diabetes, but 26%
reported current or previous treatment for depression. With regard to disease modifying
therapies, 48.3% were currently using hydroxyurea and 28.8% were currently receiving regular
blood transfusions. Of those currently using hydroxyurea, 64.8% reported they were adherent 6 –
7 days/week with the remainder reporting they were not (0 – 1 days, 9.4%) or were only partially
(2 – 5 days, 25.8%) adherent.
The majority of participants (over 80%) reported no barriers to needed healthcare, with
18.2% reporting 1 or more concrete barriers (access/accommodations/insurance) and 18.1%
reporting 1 or more individual barriers. Almost all (92.2%) participants had outpatient visits with
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their primary care provider or SCD specialist within the past year. More than half (55.2%) had
three or more ED or inpatient admissions for acute pain episodes in the past year, however, data
on this variable was missing for more than 27% of the cohort.
For ASCQ-Me® Pain Episode Frequency and Severity T-scores, means and standard
deviations were similar to the reference sample, with a pain episode frequency mean (SD) of
49.2 (11) and pain severity mean (SD) of 50.8 (9.7).
Patient Reported Outcomes: Multivariable Models
Figure 2 shows means and variability of T-scores for each PRO. On the ASCQ-Me®
measures, means and standard deviations were similar to the reference sample. Using the
Emotional and Social Functioning Impact measures, participants reported mean (SD) scores of
50.5 (8.8) and 51.2 (9.7) respectively and only a few reported T-scores less than 40, with 12.7%
reporting worse emotional impact and 14.8% reporting worse social functioning compared to the
population norms. Somewhat higher percentages of participants reported T-scores less than 40
for Pain (mean (SD) of 47.1 (9.0)) and Sleep Impact (mean (SD) of 49.2 (9.7)), with 21.5%
reporting worse impact of pain and 16.9% reporting worse sleep impact. For NeuroQol
Cognitive Functioning, the mean (SD) was 50.3 (9.1) with 12.9% of the sample reporting
impaired cognitive functioning (T-score < 40). For PROMIS Emotional distress, the mean (SD)
was 50.9 (9.6), with 20.1% reporting worse emotional distress (T-score > 60). Finally, for
PROMIS® Fatigue (tiredness), the mean (SD) was 55.4 (9.5) with 22% reporting worse tiredness
(T-score > 60).
Results for univariate models can be found in supplemental materials (Table S1). In the
univariate model, age, gender, income, employment status, marital status, treatment for
depression, concrete and individual barriers to care, pain frequency and severity, and number of
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reported complications were entered in the model according to our selection criteria for the
outcome Emotional Impact. In the multivariable model (Table 3), individuals with incomes of
$25,000 and under (OR: 1.87; 95% CI 1.20-3.00), those who were divorced or
separated/widowed (OR: 1.87; 95% CI 1.06-3.21), ever treated for depression (OR: 2.36 95% CI
1.70-3.29) and with higher pain frequency (OR: 1.06; 95% CI 1.03-1.08) and severity (OR: 1.07;
95% CI 1.04-1.09) had higher odds for worse outcomes on the Emotional Impact measure.
Fewer individual barriers to care (OR: 0.46; 95% CI 0.28-0.80) and fewer complications on the
MHC (0-2 complications (OR: 0.54; 95% CI 0.32-0.90) compared to 4 or more complications
(OR: 0.54; 95% CI 0.38-0.78) were significantly associated with better outcomes with regard to
Emotional Impact. These variables remained as independently associated with Emotional Impact
when age and gender were forced into the model.
Age, gender, education, income, employment status, diabetes diagnosis, treatment for
depression, concrete and individual barriers to care, pain frequency and severity, complications
from the MHC and ED and inpatient utilization for pain met criteria for inclusion in the
univariate model for Social Functioning Impact. In the adjusted model, individuals with disabled
(OR: 3.34 95% CI 2.32-4.87) or student status (OR: 1.48; 95% CI 0.88-2.44) had higher odds for
worse social functioning impact as did individuals treated for depression (OR: 1.64; 95% CI
1.23-2.18) and with increasing pain frequency (OR: 1.04; 95% CI 1.03-1.06) and severity (OR:
1.09; 95% CI 1.07-1.11). Fewer individual barriers to care (OR:0.50;95% CI 0.31-0.82) were
associated with lower odds of worse social functioning impact. These variables remained as
independently associated with social functioning impact when age and gender were in the model.
Age, gender, education, income, employment status, marital status, diagnosis of diabetes,
treatment for depression, disease modifying therapies, concrete and individual barriers to care,
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pain frequency and severity and ED and inpatient utilization for pain met selection criteria in the
univariate model for Pain Impact. In the adjusted model, individuals with disabled and “other”
employment status (OR :1.09; 95% CI 0.68-1.72 and OR: 2.07; 95% CI 1.49-2.90) had higher
odds of poor outcomes with regard to pain impact as did those who were divorced, separated or
widowed (OR: 1.76; 95% CI 1.09-2.81). Odds for worse outcomes on Pain Impact increased
with increasing pain frequency (OR: 1.1; 95% CI 1.08-1.12) and severity (OR: 1.10; 95% CI
1.08-1.12). These variables, except for marital status, remained in the model when age and
gender were included.
Gender, education, income, employment status, treatment for depression, concrete and
individual barriers to care, pain frequency and severity and complications from the MHC met
selection criteria in the univariate model for Sleep Impact. In the adjusted model, individuals
with incomes of $25,000 and under, as well as incomes of $25,001 - $50,000 (OR :2.03; 95% CI
1.38-3.05 and OR: 2.03; 95% CI 1.30-3.22) had higher odds of poor outcomes with regard to
sleep impact as did those ever treated for depression (OR: 2.07; 95% CI 1.55-2.75). Odds for
worse outcomes on Sleep Impact increased with increasing pain frequency (OR: 1.03; 95% CI
1.01-1.04) and severity (OR: 1.03; 95% CI 1.01-1.05). Those with fewer concrete barriers to care
(OR: 0.60; 95% CI 0.40-0.93) and 0-2 (OR: 0.48; 95% CI 0.30-0.73) or 3-4 (OR: 0.71; 95% CI
0.53-0.96) complications on the MHC had lower odds for poor outcomes. These variables
remained in the model when age and gender were included.
For Neuro-QoL® Cognitive Function, in the univariate model, gender, education, income,
employment status, treatment for depression, concrete and individual barriers to care, pain
frequency and severity, number of reported complications, and acute utilization for pain met
criteria for inclusion. In the adjusted model, individuals with high school (OR: 2.0; 95% CI 1.25-
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3.29) or less (OR: 1.98; 95% CI 1.07-3.62) education, ever treated for depression (OR: 1.74;
95% CI 1.23-2.45), higher pain frequency (OR: 1.03; 95% CI 1.01-1.05) and less acute
utilization (OR: 2.31 for 0 ED or inpatient admissions in the past year; 95% CI 1.47-3.59 and
OR: 1.61 for 1-2 of either ED or inpatient admissions in the past year; 95% CI 1.08-2.37) had
higher odds for worse cognitive functioning. Those reporting fewer individual barriers to care
(OR: 0.34; 95% CI 0.20-0.57) had lower odds for poor cognitive functioning. These variables
remained as independently associated with cognitive functioning when age was also in the
model.
Age, gender, education, income, employment status, marital status, diabetes diagnosis,
treatment for depression, SCD diagnosis, concrete and individual barriers to care, pain frequency
and severity, number of reported complications and ED and inpatient utilization for pain met
criteria for inclusion in the univariate model for PROMIS Emotional Distress. In the adjusted
model, individuals with incomes of $25,000 and under (OR: 1.87; 95% CI 1.32-2.69), ever
treated for depression (OR: 3.30 95% CI 2.52-4.34), SCD diagnosis of other variants (OR: 1.89;
95% CI 1.14-3.07) and with higher pain frequency (OR: 1.02; 95% CI 1.01-1.03) and severity
(OR: 1.02; 95% CI 1.01-1.04) had higher odds for worse outcomes on the Emotional Distress
measure. Those with fewer individual barriers to care (OR: 0.45; 95% CI 0.28-0.73) and 0-2
(OR: 0.56; 95% CI 0.38-0.83) or 3-4 (OR: 0.61; 95% CI 0.46-0.83) complications on the MHC
had lower odds for poor outcomes with regard to emotional distress. These variables remained as
independently associated with emotional distress when age and gender were in the model.
Finally, in the univariate model for PROMIS Fatigue (tiredness), age, gender, education,
employment status, marital status, treatment for depression, SCD diagnosis, disease modifying
therapies, concrete and individual barriers to care, pain frequency and severity and number of
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reported complications met selection criteria for inclusion. In the adjusted model, individuals
ever treated for depression (OR: 1.75; 95% CI 1.37-2.23) and with higher pain frequency (OR:
1.02; 95% CI 1.01-1.03) and severity (OR: 1.02; 95% CI 1.01-1.03) had higher odds for worse
reports of tiredness. Those identifying as male (OR: 0.40; 95% CI 0.31-0.51) and with fewer
individual barriers to care (OR: 0.41; 95% CI 0.27-0.62) had lower odds for tiredness. These
variables remained as independently associated with tiredness when age was also in the model.
Hydroxyurea Adherence and Patient Reported Outcomes
We conducted a sub-analysis of the 979 participants who reported that they were
currently prescribed hydroxyurea. Characteristics of individuals currently prescribed
hydroxyurea compared with those not prescribed hydroxyurea can be found in supplemental
materials (Table S1). More participants on hydroxyurea were in the 18 – 24-year-old age group
(34.7%) compared with those not on hydroxyurea (27.9%, p = .004). More male participants
(55%) were on hydroxyurea compared with female participants (43.7%; p < .0001). Employment
status differed between those participants on hydroxyurea compared to those not on hydroxyurea
(p < .001). Fewer participants on hydroxyurea were working (33.6%) compared with those not
on hydroxyurea (40.7%) and conversely, more participants on hydroxyurea reported disabled
(27.2%) and student status (15.7%) compared with those not on the medication (22.9% and
11.5% respectively). Seventy-seven percent of participants on hydroxyurea reported that had
never been married compared with 72% of those not on hydroxyurea (p < .01). As would be
expected, most participants on hydroxyurea had genotype SS or Sβ0 thalassemia (86%)
compared with other genotypes (14%; p < .0001).
In univariate models including hydroxyurea adherence and the other socio-demographic,
clinical and health behavior variables, hydroxyurea adherence entered in the models according to
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our selection criteria only for the PROs ASCQ-Me Sleep Impact and PROMIS Fatigue
(tiredness). In the multivariable model, individuals with incomes of $25,000 and under (OR:
2.42; 95% CI 1.43-4.31), ever treated for depression (OR: 2.5 95% CI 1.70-3.70) and with higher
pain frequency (OR: 1.03; 95% CI 1.00-1.05) and severity (OR: 1.03; 95% CI 1.00-1.05) had
higher odds for worse outcomes on the Sleep Impact measure. Those with a visit to a primary
care provider or sickle cell specialist in the past year had lower odds for worse outcomes on
sleep impact (OR: 0.33 95% CI 0.15-0.79).
In the multivariable model for tiredness, individuals ever treated for depression (OR: 1.62
95% CI 1.11-2.33), not adherent with hydroxyurea (OR: 2.04 95% CI 1.17-3.49) and with higher
pain frequency (OR: 1.02; 95% CI 1.00-1.04) had higher odds for worse outcomes on the Fatigue
measure. Those with male gender (OR: 0.39 95% CI 0.27-0.56) and 0 – 1 versus 2 or more
access/accommodation/insurance barriers had lower odds for worse outcomes on the Fatigue
measure (OR: 0.50 95% CI 0.29-0.85).
CHAPTER VI
Discussion
This dissertation study hypothesized that patient and SCD related factors as well as
barriers to care would independently contribute to functioning as measured using PRO domains
from the ASCQ-Me®, PROMIS® and NeuroQoL™ measurement systems. We expected that the
experience of pain and other SCD related complications would account for a significant degree
of the relation between the variables and further considered the bidirectional influence of health
behaviors such as adherence and healthcare utilization on the PRO domains. Generally, our
findings were consistent with study hypotheses, with higher pain frequency and severity and
history of treatment for depression associated with higher odds of worse outcomes in almost all
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PRO domains studied, with findings remaining even when controlling for age and gender. Such
social determinants of health as lower household income and unemployment, particularly due to
disability status, were also associated with higher odds of worse outcomes on some of the PRO
domains studied. Our study includes consideration of barriers to care, and we found a protective
effect, with reports of fewer individual barriers to care associated with better outcomes in the
emotion, social, cognitive and fatigue (tiredness) domains. Reports of fewer self-reported SCD
complications/treatments were also protective, with associations with better outcomes in the
emotion and sleep impact domains.
Our findings are consistent with previous research (Dampier et al., 2011; Esham et al.,
2019; McClish et al., 2017) that has highlighted dimensions of pain experiences associated with
worse outcomes on PROs for adults with SCD, as well as depression (Adam et al., 2017; Master
et al., 2016). However, our study is the first large, multi-site cohort of adults with SCD who
completed contemporary PRO measures that have been developed and validated with state-ofthe-science psychometric methods. We thus contribute to the accumulation of information on the
precision, applicability and interpretation of PROMIS® and related measurement systems,
ASCQ-Me® and NeuroQoL™.
Reports on the PRO measures for our study participants were on average similar to
reference samples, although with considerable variability within and across domains. For several
domains, about 20% of participants of large-scale PROMIS reference samples have
demonstrated moderate to severe symptomatology or functional impairment (Cella et al., 2010;
Rothrock et al., 2010). About 20% of participants in the current study reported moderate/severe
pain and emotional impact and tiredness. However, the proportion of participants with
moderate/severe emotional (12.7%) and social functioning (14.8%) and sleep impact (16.9%) on
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ASCQ-Me were less than that seen in the reference population for PROMIS. Given that a higher
percentage of participants endorsed moderate/severe emotional distress on the PROMIS measure
compared with the ASCQ-Me emotional impact measure suggests that the two measures are
indeed assessing different constructs. Interpretation of scores from the disease specific ASCQMe measures needs further exploration, although findings from this large sample can provide a
baseline for future studies. Studies establishing sensitivity of PRO measurement to distress and
functioning for SCD populations, as well as changes in health status are particularly critical.
Approximately 13% of respondents fell below the moderate/severe threshold on the
NeuroQOL Cognitive Function short form (Cella et al., 2012). This tool was designed to capture
participants’ concerns about general cognition and to assess executive function concerns
(Prussien et al., 2018; Shimada et al., 2014). The multivariate model was consistent with prior
studies in that worse reports of cognitive function were associated with depressive symptoms
(Sanger et al., 2016) and with lower levels of education (Saunders et al., 2018). In this study,
worse reports of cognitive function were not associated with very high acute care utilization. It is
possible that the proportion of participants with cognitive dysfunction in the SCDIC Registry
was underrepresented. Prior studies have documented poor correlation in self-report of executive
function and performance of executive function assessments, with less recognition of impairment
(Eisenberg et al., 2019). Worse executive function is associated with poor medical treatment
adherence, and it may also be associated with less insight into these relationships (GutiérrezColina et al., 2016).
Complex relations were also found among measures. Pain severity, frequency of pain,
history of depression and lower income were associated with the highest odds for worse
emotional, sleep and tiredness impacts, consistent with other studies (Eisenberg et al.,
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2019). Pain experiences in combination with patient-related variables such as unemployment
(particularly related to disabled status) and marital status (divorced/separated) played a
significant role in worse outcomes on such PROs as social functioning and emotional
impact. Similar to previous research, other demographic factors (age, gender) were consistently
associated with the PRO measures (Dampier et al., 2011; Wallen et al., 2014). We found that
SCD genotype per se, where Hgb SS and Sß0 thalassemia are considered most severe, was not
associated with the PRO measures. In fact, in the one instance where genotype was associated
with a PRO measure in the present study, it was other SCD variants (SC, Sß+ thalassemia and
others) that were associated with worse outcomes on the PROMIS Emotional Distress measure.
Aside from genotype, we did consistently find that fewer patient reports of SCD related
complications and treatments was associated with better outcomes on the PRO measures. Thus,
when considering clinical and research interventions, there is ample evidence that HRQoL in
SCD must be viewed as a complex biopsychosocial phenomenon and there is an urgent need for
specific focus on the pain experience and depression.
While disparities in quality of life and quality of care are well-recognized in SCD,
particularly for adults, the impact of barriers to care has not been widely studied. We used a
modified version of the first disease specific measure of barriers to care in SCD and
demonstrated that the majority of participants in the SCDIC registry reported no barriers to
needed care, and fewer barriers to care were associated with better outcomes on all PRO
measures except pain impact. In a recent study of 303 adults with SCD, the most reported
barriers to receiving care were discrimination by and mistrust in healthcare professionals, as well
as healthcare costs (Rizio et al., 2020). In another recent study, reports of delaying ED care were
inter-related with higher stigma experiences, more frequent pain episodes, lower health care

PATIENT REPORTED OUTCOMES IN SICKLE CELL DISEASE

48

satisfaction, and yet more frequent ED visits (Abdallah et al., 2020). The over 400 adolescents
and adults with SCD who participated in the multi-site SCDIC needs assessment similarly
reported discrimination and mistrust in the acute healthcare system as barriers (Kanter et al.,
2020). The SCDIC has launched an intervention to improve ED care by enhancing comanagement between ED and SCD specialists and empowering adults with SCD with improved
access to their individualized pain plans in the ED (Luo et al., 2020). Much still needs to be
understood and addressed regarding the impact of barriers to care, particularly stigma and
discrimination, on HRQoL in SCD.
Higher healthcare utilization is often a reflection of the increased burden of SCD-related
complications, which can be associated with worse health outcomes, including morbidity and
mortality. While the majority of our sample had outpatient primary or SCD specialty care visits
in the past year, over half still had what would be considered high acute utilization, with more
than three combined ED visits and inpatient stays in the past year. Contrary to hypothesis, higher
healthcare utilization was not associated with worse outcomes in any PRO domain, while lower
healthcare utilization was in fact associated with worse outcomes in the cognitive functioning
domain. Previous studies have reported various other factors associated with increased
healthcare utilization, including female gender (Fosdal & Wojner-Alexandrov, 2007), living
away from the hospital (Nietert et al., 1999), and having co-morbidities (Raphael et al., 2012),
depression (Jonassaint, Jones, et al., 2016), or other psychiatric illness, such as anxiety and mood
disorder (Myrvik et al., 2012). Using PROMIS measures, a recent study focused on youth with
SCD in the U.S. reported an association between increased healthcare utilization and worse
HRQoL domain scores, particularly depression, social isolation, pain, fatigue and physical
function mobility (Badawy et al., 2018). Similar associations were demonstrated in a recent
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systematic review of the literature (Jonassaint, Jones, et al., 2016) and in other studies using SF36 measure in Nigeria (Adeyemo et al., 2015) and Saudi Arabia (Abdel-Monhem Amr et al.,
2011; Ahmed et al., 2016).
In addition to healthcare utilization, we were interested in the relation between adherence
behavior and PRO domain scores. Previous studies reported better HRQoL outcomes among
children and adults with SCD who were receiving hydroxyurea, regardless of adherence level,
compared to those who were not (Ballas et al., 2006; Thornburg et al., 2011). In our sub-sample
of 979 individuals with SCD currently prescribed hydroxyurea, non-adherence in combination
with history of depression and higher pain frequency were associated only with worse outcomes
for tiredness, which is consistent with recently published data (Badawy et al., 2017a). Badawy
and colleagues reported an association between lower hydroxyurea adherence, using subjective
and objective measures, and worse HRQoL outcomes, particularly fatigue, depression and social
isolation (Badawy et al., 2017a). Hydroxyurea adherence is multifactorial in nature, and it is a
dynamic behavior that likely varies across patients and within the same patient over time. Our
sub-sample of participants prescribed hydroxyurea was younger, male, never married and
unemployed with disabled or student status, compared with those not on the hydroxyurea. Male
gender and fewer barriers to care were associated with better outcomes for tiredness for the
subsample. In an in-depth analysis of qualitative interviews from the SCDIC needs assessment, a
majority of the 90 participants (70%) with SCD described unintentional barriers to hydroxyurea
adherence, including misunderstanding of medical instructions, the burden of complex treatment
regimens, never being offered the drug, and the low quality and weak patient-provider
relationship and communication (Hodges et al., 2020). Similarly, among youth with SCD,
patient-reported negative perceptions of hydroxyurea and more frequent barriers were associated
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with lower hydroxyurea adherence rates as well as worse HRQoL outcomes (Badawy et al.,
2018; Badawy, et al., 2017).
Limitations
Despite our gathering data from participants with SCD from multiple sites across the
U.S., the generalizability of the sample may still represent a limitation, given that the majority
were recruited through sickle cell centers and had in fact seen a sickle cell specialist or primary
care provider in the previous year. Due to the vast shortage of adult sickle cell specialists in the
U.S., it is known that most adults with SCD simply do not have access to needed preventive care
and the impact of disparities in access to care on HRQoL can only be determined when more
patients who are “unaffiliated” with SCD care are recruited into research. The cross-sectional
nature of the study precludes any conclusions about causal relations between study variables and
the PROs. In order to reduce participant burden, we did not include all items for every PRO
measure, thereby limiting full comparison with studies using the complete PRO measures.
However, PROMIS measures have been constructed to maintain precision even when only
single, or a few items are used. Our registry data collection included both self-report and
information extracted from medical records, however for completeness of data, we only used
self-reports of SCD complications experienced, and these reports may or may not correspond
with actual complications endured by participants. When we did use data from the medical
record, such as in relation to healthcare utilization, we were subject to missing data on the order
of greater than 25% of our sample. There is also a possibility that during data collection,
participants might have misunderstood the items listed on the medical health history checklist or
responded based on incorrect recollection. Study limitations notwithstanding, our research
contributes to the literature in its examination of interrelations between modern PRO measures
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and SCD related and other variables within a conceptual model and utilizing a large,
geographically diverse sample.
Study implications:
Reliable and valid PRO measurement is essential to the design of clinical trials and other
research, so much so, that the National Institutes of Health invested in a high-profile Common
Fund effort to develop PROMIS measures and related ASCQ-Me and NeuroQoL measurement
systems (Sarri et al., 2018; Yount et al., 2019). Results from the present study can provide a
baseline for longitudinal investigations that can establish sensitivity to change of the PRO
measures and that can advance our understanding of how SCD and its treatments impact
outcomes for patients.
From a clinical standpoint, the current research provides data supporting that PRO
measures can provide meaningful information for providers and patients in areas of focus to
improve HRQoL. The study also highlights how critical it is to view lives, care and treatments
for individuals with SCD within a biopsychosocial model. For example, our sample evidenced a
high prevalence of history of depression, and substantial impact of pain experiences and social
determinants of health, yet protective influence of fewer barriers to care and disease
complications. Multi-dimensional interventions that include case management as well as expert
medical care could improve PROs. In one study, case managers were considered to be the only
healthcare team member who has a broad knowledge of the patients’ experience of pain, state of
health, behavioral health needs, and how psychosocial factors may affect both inpatient and
outpatient health care use and outcomes (Brennan-Cook et al., 2018).
It is important for providers, especially sickle cell specialists, to understand their patients’
perspectives about their expected health outcomes after treatments. Patients might be reluctant to
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disclose their dissatisfaction if their expectations were not met. Patients might also feel
misunderstood or unheard by their providers. Previous studies have demonstrated that patients’
mistrust in healthcare professionals can lead to lower treatment adherence and adversely impact
health outcomes due to delays in care (Oyedeji & Strouse, 2020). Collecting PROs during
clinical encounters, on the other hand, may enhance provider-patient communication and
promote effective symptom management. It is important to attend to these issues to close the gap
in health equity for SCD care.
Directions for future research:
We were unable to focus on a number of potential contributing factors to outcomes with
regard to PROs, such as other mental health symptoms, e.g., anxiety in addition to depression;
actual experience of stigma and discrimination as barriers to care; coping and self-efficacy.
Prospective longitudinal studies are warranted to assess and better understand the dynamic
relation between hydroxyurea adherence and HRQoL outcomes over time, including the longterm effect of one on the other. Longitudinal studies will also allow for the examination of
changes in PROs over time, will advance our understanding of the impacts of SCD and its
treatments, as well as of the impact of therapies to improve PROs. Future research including
PRO measures can refine models for intervention to improve overall care of those living with
SCD.
Conclusion:
The present study provides important new information regarding inter-relations between
SCD complications, disease modifying therapies, social determinants of health and barriers to
care for adults with SCD. Our findings emphasize the importance of the biopsychosocial model

PATIENT REPORTED OUTCOMES IN SICKLE CELL DISEASE
to enhance our understanding of the needs of this complex population, and to design multidimensional approaches for providing more effective interventions to improve outcomes.

53

PATIENT REPORTED OUTCOMES IN SICKLE CELL DISEASE

54

Tables & Figures
Table 1. Participant Socio-Demographics
Characteristic

N = 2054

Age
Mean (SD) years
Median (IQR)

29.1 (7.2)
28 (23-35)
n (%)

18 to 24 years
25 to 34 years
35 to 45 years
Gender Identity
Male
Female
Race/Ethnicity
Black/African American
Multi-racial
Other Race (American Indian/Alaska Native, Asian,
White)
Hispanic ethnicity

641 (31.2)
900 (43.8)
513 (25.0)
888 (43.2)
1166 (56.8)
1918 (95.7)
67 (3.3)
20 (0.9)
91 (4.5)

Highest Education
Some high school or less
High School (Graduate, GED or equivalent)
Some college
College graduate or advanced degree

209 (10.4)
612 (30.3)
711 (35.2)
487 (24.1)

Employment
Working now
Disabled
Student
Other (unemployed, retired)

748 (37.2)
507 (25.2)
272 (13.5)
485 (24.1)

Marital Status
Married or living together
Never married
Not married (divorced/separated, widowed)

313 (16.2)
1499 (77.6)
120 (6.2)
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Annual Household Income
$25,000 or less
$25,000 - $50,000
$50,001 or more
Insurance
Medicaid, CHIP, other government-sponsored
Private
Medicare
None
Other
a
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998 (54.6)
403 (22.1)
426 (23.3)
1216 (59.2)a
567 (27.6)
468 (22.8)
83 (4.0)
16 (0.8)

Percentages add up to greater than 100% as more than one option could be selected
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Table 2. Clinical Characteristics, Barriers to Care and Health Behaviors
Characteristic

N = 2054
n (%)

Sickle cell disease diagnosis
Hb SS or Sβ0 thalassemia
Hb SC
Hb Sβ+ thalassemia and other variants
ASCQ-Me Medical History Checklist
Mean (SD)
Median (IQR)
Range (minimum – maximum)

1490 (72.6)
432 (21.1)
130 (6.3)
3.1 (2)
3 (2-4)
0 – 12
n (%)

Diabetes
Yes
No

53 (2.6)
1953 (97.4)

Ever treated for depression
Yes, current
Yes, previous
No

181 (9.2)
330 (16.8)
1455 (74.0)

Hydroxyurea use and adherence
Yes, current use
Adherent (6 – 7 of 7 days)
Partially adherent (2 – 5 of 7 days)
Not adherent (0 – 1 of 7 days)
No, not currently using

628 (31.3)
250 (12.5)
91 (4.5)
1035 (51.7)

Regular blood transfusions for SCD
Yes
No

587 (28.8)
1449 (71.2)

Barriers to Care
Access/Accommodations/Insurance
No barriers
1 – 2 barriers
3 or more barriers
Individual barriers
No barriers
1 – 2 barriers
3 or more barriers

1681 (81.8)
302 (14.7)
71 (3.3)
1683 (81.9)
323 (15.7)
48 (2.3)
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From Medical Record Abstractions:
Outpatient visit to hematologist or primary care provider within past
12 months
Yes
No
Unknown

1893 (92.2)
92 (4.5)
69 (3.4)

Emergency department (ED) and inpatient admissions for pain
within past 12 months
No ED or inpatient admissions
1 – 2 ED or inpatient admissions
3 or more ED or inpatient admissions

279 (18.7)
388 (26.0)
823 (55.2)

Patients with missing data are not included in calculations of percentages unless otherwise
specified
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Table 3. Significant Multivariate Relations Between Patient-Reported Outcomes
and Demographic and Clinical Characteristics
Predictor

Model
ASCQ-Me®
Emotional Impact

Income
$25,000 and under
$25,001 - $50,000
$50,001+
Marital status
Married/Living as married
Divorced/Separated/Widow
Never married
Ever treated for depression
# Individual barriers to care
0-1 versus 2 or more
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
ASCQ-Me® SCD-MHC
Low (0-2)
Medium (3-4)
High (>4)

ASCQ-Me® Social
Functioning Impact

Employment

Overall type III
p-value
.02

1.87 (1.20-3.00)**
1.45 (0.85-2.52)
Ref
.03

<.0001
.004
<.0001
<.0001
.002

Employment
Disabled
Student
Other
Working

0.46 (0.27-0.80)**
1.06 (1.03-1.08)**
1.07 (1.04-1.09)**

<.001
3.34 (2.32-4.87)**
1.48 (0.88-2.44)

Student

ASCQ-Me® Pain
Impact

1.44 (0.93-2.20)
1.87 (1.06-3.21)*
Ref
2.36 (1.70-3.29)**

0.54 (0.32-0.90)*
0.54 (0.38-0.78)**
Ref

Disabled

Other
Working
Ever treated for depression
# Individual barriers to care
0-1 versus 2 or more
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity

OR (95% CI)

.0007
.005
<.0001
<.0001
<.0001

2.33 (1.58-3.46)**
Ref
1.64 (1.23-2.18)**
0.50 (0.31-0.82)**
1.04 (1.03-1.06)**
1.09 (1.07-1.11)**

2.4 (1.75-3.31)**
1.09 (0.68-1.72)
2.07 (1.49-2.90)**
Ref

PATIENT REPORTED OUTCOMES IN SICKLE CELL DISEASE
Marital status
Married/Living as married
Divorced/Separated/Widow
Never married
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
ASCQ-Me®
Sleep Impact

Income
$25,000 and under
$25,001 - $50,000
$50,001+
Ever treated for depression
# Concrete barriers to care
0-1 versus 2 or more
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
ASCQ-Me® SCD-MHC
Low (0-2)
Medium (3-4)
High (>4)

Neuro-QoL™
Cognitive Functioning

PROMIS®
Emotional Distress

59

.049

<.0001
<.0001

1.20 (0.86-1.66)
1.76 (1.09-2.81)*
Ref
1.10 (1.08-1.12)**
1.10 (1.08-1.12)**

.0014

<.0001
.02
.001
.0008
.002

2.03 (1.38-3.05)**
2.03 (1.30-3.22)**
Ref
2.07 (1.55-2.75)**
0.60 (0.40-0.93)*
1.25 (1.01-1.04)**
1.03 (1.01-1.05)**
0.48 (0.30-0.73)**
0.71 (0.52-0.96)*
Ref

.03
Education
<High School
High school
Some college
College/Advanced
Ever treated for depression
# Individual barriers to care
0-1 versus 2 or more
ASCQ-Me® Pain Frequency
Acute utilization (ED or Inpatient
visits) past 12 months
0 for both
1-2 of either
3+ of either
Income
$25,000 and under
$25,001 - $50,000
$50,001+
Ever treated for depression

.002
<.0001
.006
.0007

1.98 (1.07-3.62)*
2.00 (1.25-3.29)**
1.45 (0.91-2.36)
Ref
1.74 (1.23-2.45)**
0.34 (0.20-0.57)**
1.03 (1.01-1.05)**

2.31 (1.47-3.59)**
1.61 (1.08-2.37)*
Ref
.0012

<.0001

1.87 (1.32-2.69)**
1.32 (0.86-2.02)
Ref
3.30 (2.52-4.34)**
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SCD dx
SS/Sβ0 Thalassemia
SC
Other variants
# Individual barriers to care
0-1 versus 2 or more
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
ASCQ-Me® SCD-MHC
Low (0-2)
Medium (3-4)
High (>4)
PROMIS®
Fatigue/Tiredness

.03
Ref
1.22 (0.88-1.69)
1.89 (1.14-3.07)*
.001
.01
.01
.001

<.0001
Gender Identity Male
Ever treated for depression
# Individual barriers to care
0-1 versus 2 or more
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
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<.0001
<.0001
.003
.004

0.45 (0.28-0.73)**
1.02 (1.01-1.03)*
1.02 (1.01-1.04)*
0.56 (0.38-0.83)**
0.62 (0.46-0.83)**
Ref
0.40 (0.31-0.51)**
1.75 (1.37-2.23)**
0.41 (0.27-0.62)**
1.02 (1.01-1.03)**
1.02 (1.01-1.03)**

#: number of
ASCQ-Me®: Adult Sickle Cell Quality of Life Measurement Information System
ASCQ-Me® SCD MHC: Adult Sickle Cell Quality of Life Measurement Information System
Sickle Cell Disease Medical History Checklist
Neuro-QoL™: Quality of Life in Neurological Disorders
PROMIS®: Patient Reported Outcomes Measurement Information System
*p < .05
**p < .01
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Table S1. Significant Multivariate Relations Between Patient-Reported Outcomes
and Demographic and Clinical Characteristics (Supplemental Table)

Variables
Age
18-24
25-34
35+
Gender Identity
Male
Education
<High School

Emotional Impact
(n = 1530; EI<40 = 200)
<40
>40
pvalue
58
(22.7%)
127
(49.8%)
70
(27.5%)
78
(30.6%)

574
(32.7%)
748
(42.6%)
434
(24.7%)
788
(44.9%)

28 (11.1)

176
(10.1)
526
(30.3)
606
(34.9)
426
(24.6)

0.6

820
(52.4)
358
(22.9)
386
(24.7)

<0.000
1

High school

81 (32)

Some college

92 (36.4)

Ref:
College/Avd.
Income
$25,000 and
under
$25,001 $50,000
Ref: $50,001+

52 (20.6)

Employment

160 (68.1)
40 (17)
35 (14.9)

0.0006

<0.000
1

Social Functioning Impact
(n=1924, SF<40 n = 281)
<40
>40
p-value
77
(25.7)
146
(48.7)
77
(25.7)
100
(33.3)

559
(32.3)
740
(42.7)
432 (25)

0.06

777
(44.9)

0.0002

34
(11.5)
106
(35.8)
101
(34.1)
55
(18.6)

173
(10.1)
504
(29.5)
604
(35.3)
429
(25.1)

0.04

185
(68.3)
43
(15.9)
43
(15.9)

807
(52.2)
358
(23.2)
381
(24.6)

<.0001

Pain Impact
(n=1885, PI<40 n = 410)
<40
>40
pvalue

Sleep Impact
(n=1598, SI<40 n = 270)
<40
>40
pvalue

102
(23.3%)
201
(46.0%)
134
(30.7%)
167
(38.2%)

535
(33.6%)
681
(42.8%)
376
(23.6%)
709
(44.5%)

<0.000
1

102 (30)

0.02

126 (37.1)

57
(13.4)
135
(31.8)
151
(35.5)
82
(19.3)

150 (9.5)

0.02

44 (13.1)

162 (47.6)
76 (22.4)

469 (29.9)

100 (29.8)

552 (35.1)

125 (37.2)

400 (25.5)

67 (19.9)

257
(66.2)
70 (18)

725 (51.2)

<0.000
1

202 (65.4)

329 (23.2)

65 (21)

61
(15.7)

363 (25.6)

42 (13.6)

532
(31.8)
713
(42.6)
428
(25.6)
742
(44.4)

0.2

0.01

161
(9.7)
506
(30.6)
570
(34.5)
415
(25.1)

0.08

777
(52.1)
332
(22.3)
381
(25.6)

<0.000
1
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Ref: Working
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Disabled

99 (39.1)

Student

28 (11.1)

Other

66 (26.1)

Marital status
Married/Living
as married
Divorced/Separa
ted/Widow
Ref: Never
married
Diabetes "No"
Ever treated for
depression
"No"
SCD dx
Ref: SS/Sβ0
Thalassemia
SC

680
(39.4)
396
(22.9)
243
(14.1)
409
(23.7)

<0.000
1

42(16.8)

268(16.2)

0.046

24(9.6)

93(5.6)

184(73.6)

1290(78.
1)
1,678
(97.6)
1,308
(77.2)

237 (95.6)
124 (51.2)

183 (72)
52 (20.5)

Disease
176 (70.1)
Modifying
Therapies "yes"
Access/Accomm
odations/Insura
nce barriers to
care

1,277
(72.7)
371
(21.1)
1103
(63.8%)

51
(17.2)
132
(44.4)
30
(10.1)
84
(28.3)

694
(40.8)
370
(21.7)
241
(14.2)
397
(23.3)

<0.000
1

43(14.8)

265(16.3
)
96(5.9)

0.3

24(8.2)

224(77.0 1268(77.
)
8)
0.06
281
1,652
(95.6)
(97.6)
<0.000
168
1,278
1
(59.4)
(76.4)
0.7

0.05
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220
(73.3)
59
(19.7)
188
(64.2)

1,253
(72.4)
369
(21.3)
1,102
(64.7)

0.05
<0.000
1
0.7

0.9

91
(21.4)
171
(40.1)
36 (8.5)

652 (41.7)

<0.000
1

92 (27.5)

325 (20.8)

105 (31.3)

235 (15)

36 (10.7)

128 (30)

351 (22.5)

102 (30.4)

73(17.5)

239(16.0)

35(8.4)

83(5.6)

23(7.1)

310(74.2
)
412
(96.0)
273
(66.6)

1171(78.4
)
1518
(78.4)
1163
(75.9)

258(79.4)

318
(72.8)
89
(20.4)
290
(68.6)

0.07

44(13.5)

0.053

327 (97.6)

0.0001

184 (57.3)

1,152
(72.4)
340 (21.4)

0.8

244 (72)

999 (63.5)

0.05

72 (21.2)
225 (67.6)

647
(39.3)
392
(23.8)
243
(14.2)
373
(22.7)

<0.000
1

267(16.9
)
94(6.0)

0.3

1217(77.
1)
1,589
0.8
(97.3)
1,246
<0.000
(77.1)
1
1,216
(72.7)
354
(21.2)
1,053
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Ref: 0-1
2 or more
# of individual
barriers to care
Ref: 0-1
2 or more
ASCQ-Me Pain
episodes
frequency score
Mean(SD)
Median
ASCQ-Me Pain
episodes
severity score
Mean (SD)

213
(83.5%)
42
(16.5%)

1630
(92.8%)
126
(7.2%)

<0.000
1

221
(86.7%)
34
(13.3%)

1676
(95.4%)
80
(4.6%)

<0.000
1

54.6 (8.2)

48.4
(11.2)
51.8

<0.000
1

55.7

55.1 (7.3)

Median
Expanded
ASCQ-Me
SCD-MHC
score - 13
items*
Low (0-2)

57

29 (12.6)

Medium (3-4)

59 (25.5)

High (>4)

143 (61.9)

50.2 (9.8) <0.000
1
52.3

392
(24.1)
660
(40.6)
573
(35.3)

<0.000
1

259
(86.3)
41
(13.7)

1,598
(92.3)
133
(7.7)

0.0006

269
(89.7)
31
(10.3)

1,645
(95)
86 (5)

0.0002

54.3
(8.3)
55.7

48.4
(11.2)
51.8

<0.000
1

55.9
(7.3)
57

50 (9.7)

<0.000
1

27 (9.7)

397
(24.9)
617
(38.8)
578
(36.3)

107
(38.4)
145 (52)

52.3

<0.000
1

63
384
(87.9)
53
(12.1)

1,472
(92.5)
120 (7.5)

0.002

290 (85.3)

402 (92)

0.03

35 (8)

1,509
(94.8)
83 (5.2)

55.7
(7.8)
59.6

47.4
(11.1)
51.8

<0.000
1

55.8
(6.5)
57

49.5 (9.9)

<0.000
1

51 (13)

371 (25.2)

126
(32.1)
215
(54.8)

597 (40.5)

107 (34.2)

507 (34.4)

166 (53)

50 (14.7)

309 (90.9)
31 (9.1)

52.5 (9.3)
55.7

50

53.2 (8.8)
54.6

<0.000
1

40 (12.8)

1,555
(92.9)
118
(7.1)

0.002

1,589
(95)
84 (5)

0.003

48.4
(11.2)
51.8

<0.000
1

50.3
(9.8)
52.3

<0.000
1

382
(24.7)
613
(29.7)
549
(35.6)

<0.000
1
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Table S1 (continued). Significant Multivariate Relations Between Patient-Reported Outcomes
and Demographic and Clinical Characteristics (Supplemental Table)

Variables
Age
18-24
25-34
35+
Gender Identity
Male
Education
<High School
High school
Some college
Ref:
College/Advanced
Income
$25,000 and under
$25,001 - $50,000
Ref: $50,001+
Employment
Ref: Working
Disabled
Student
Other
Marital status
Married/Living as
married
Divorced/Separate
d/Widow

Neuro-QOL Cognitive Functioning
(n=2040, CF<40 = 264)
<40 (worse)
>=40
p-value
(better)
86 (32.6)
106 (40.2)
72 (27.3)
91 (34.5)

551 (31)
789 (44.4)
436 (24.5)
794 (44.7)

0.4

32 (12.3)
86 (33.1)
95 (36.5)
47 (18.1)

176 (10)
526 (30)
615 (35)
438 (25)

158 (65.8)
48 (20)
34 (14.2)

PROMIS Emotional Distress
(n = 2014; ED>60 = 405)
>60 (worse)
<= 60
p-value
(better)
107 (26.4)
183 (45.2)
115 (28.4)
152 (37.5)

526 (32.7)
693 (43.1)
390 (24.2)
716 (44.5)

0.04

0.09

49 (12.3)
113 (28.3)
157 (39.3)
80 (20.1)

155 (9.7)
494 (31.1)
542 (34.1)
399 (25.1)

838 (52.9)
355 (22.4)
392 (24.7)

0

251 (67.5)
67 (18)
54 (14.5)

69 (26.4)
88 (33.7)
39 (14.9)
65 (24.9)

678 (38.8)
418 (23.9)
233 (13.3)
417 (23.9)

0

32(13.0)

281(16.7)

0.2

12(4.9)

108(6.4)

0

PROMIS Fatigue
(n=2004, FI > 60 = 440)
>60 (worse)
<= 60
p-value
(better)
117 (26.6)
202 (45.9)
121 (27.5)
107 (24.3)

513 (32.8)
670 (42.8)
381 (24.4)
756 (48.3)

0.03

39 (9)
107 (24.6)
163 (37.5)
126 (29)

165 (10.7)
498 (32.2)
530 (34.3)
352 (22.8)

0.003

730 (51)
331 (23.1)
369 (25.8)

<0.0001

222 (56.3)
77 (19.5)
95 (24.1)

752 (53.8)
320 (22.9)
326 (23.3)

0.4

110 (27.6)
143 (35.8)
44 (11)
102 (25.6)

631 (39.8)
353 (22.3)
227 (14.3)
373 (23.5)

<0.0001

150 (34.6)
118 (27.2)
51 (11.8)
115 (26.5)

588 (38.2)
376 (24.4)
220 (14.3)
356 (23.1)

0.1

60(15.6)

251(16.5)

0.1

83(19.4)

223(15.2)

0.06

33(8.6)

85(5.6)

30(7.0)

86(5.9)

0.01

0.04
<0.0001
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Ref: Never married
Diabetes "No"
Ever treated for
depression "No"
SCD dx
Ref: SS/Sβ0
Thalassemia
SC
Disease Modifying
Therapies "yes"
# of
Access/Accommodat
ions/Insurance
barriers to care
Ref: 0-1
2 or more
# of individual
barriers to care
Ref: 0-1
2 or more
ASCQ-Me Pain
episodes frequency
score
Mean(SD)
Median
ASCQ-Me Pain
episodes severity
score
Mean (SD)
Median
Expanded ASCQMe SCD-MHC
score - 13 items*

203(82.2)
247 (96.5)
148 (59)

1292(76.9)
1,695 (97.5)
1,305 (76.2)

194 (73.5)
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0.4
<.0001

292(75.8)
379 (95.9)
193 (50)

1182(77.9)
1,538 (97.7)
1,241(79.9)

0.06
<0.0001

314(73.5)
416 (96.3)
256 (61.1)

1158(78.9)
1,493 (97.6)
1,171 (77.4)

0.12
<.0001

1,288 (72.6)

0.6

287 (70.9)

1,173 (72.9)

0.1

297 (67.5)

1,155 (73.9)

0.02

57 (21.6)
175 (68.4)

372 (21)
1,124 (64.2)

0.2

83 (20.5)
260 (65.3)

342 (21.3)
1,020 (64.4)

0.7

113 (25.7)
258 (59.9)

310 (19.8)
1,015 (65.8)

0.02

222 (84.1)
42 (15.9)

1,643 (92.5)
133 (7.5)

<0.0001

347 (85.7)
58 (14.3)

1,498 (93.1)
111 (6.9)

<0.0001

377 (85.7)
63 (14.3)

1,461 (93.4)
103 (6.6)

<0.0001

232 (87.9)
32 (12.1)

1,691 (95.2)
85 (4.8)

0.05

361 (89.1)
44 (10.9)

1,538 (95.6)
71 (4.4)

<0.0001

389 (88.4)
51 (11.6)

1,501 (96)
63 (4)

<.0001

51.7 (9.8)
51.8

48.9 (11.2)
51.8

<0.0001

52.8 (9.8)
55.7

48.3 (11.2)
51.8

<.0001

51.7 (10.2)
55.7

48.5 (11.2)
51.8

<0.0001

51.6 (8.9)
52.3

50.7 (9.7)
52.3

0.2

52.5 (8.4)
54.6

50.4 (9.9)
52.3

<0.0001

52.7 (8.5)
54.6

50.2 (9.9)
52.3

<.0001
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Low (0-2)
Medium (3-4)
High (>4)

33 (13.8)
86 (35.8)
121 (50.4)

392 (23.9)
642 (39.1)
606 (37)

<0.0001

53 (14.4.)
114 (30.9)
202 (54.7)

66
369 (24.8)
606 (40.7)
514 (34.5)

<0.0001

82 (20.1)
142 (34.8)
184 (45.1)

337 (23.4)
577 (40)
527 (36.6)

0.008
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Figure 1. Conceptual Model

Figure 1. Conceptual model for inter-relations of patient reported outcomes (PROs) in sickle
cell disease (SCD). The model includes the inter-relations of four PRO groups (emotional
distress, social functioning, pain impact, and fatigue, sleep and cognitive functioning) with health
behaviors (acute healthcare utilization and preventive care), SCD complications (number of
complications and pain frequency/severity), SCD related factors (genotype, hydroxyurea, chronic
transfusion history), patient related factors (education, employment, income, marital status,
diabetes and depression) and barriers to care (systemic and individual). All inter-relations are
adjusted for age and gender identity.
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Figure 2. SCDIC Flow Diagram

Figure 2 illustrates the process by which our research team came to our to include 2,045 adults
18-45 from the SCDIC participant pool. As noted above, we removed adolescents (< age of 18)
and participants with incomplete data from our study.
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Figure 3. Distribution and variability in T Scores for Patient Reported Outcomes

Figure 3 reflects the distribution of T-scores for the seven patient reported outcomes (PROs).
For ASCQ-Me® Emotional, Social Functioning, Pain and Sleep Impact and for Neuro-QoL
Cognitive Functioning, higher scores indicate better functioning. For PROMIS® Emotional
Distress and Fatigue/Tiredness, higher scores indicate worse functioning.
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